---
title: ç”²åŸºè‹¯ä¸™èƒº
description: 
published: true
date: 2026-01-21T09:04:55.642Z
tags: 
editor: markdown
dateCreated: 2026-01-21T09:04:53.374Z
---

# ç”²åŸºè‹¯ä¸™èƒºï¼ˆMethamphetamineï¼‰

>
> å§æ§½ï¼Œå†°ï¼
>

[â—€è¿”å›è¯ç‰©](./home.md)

<mark>è´¨é‡æ¯”è¾ƒé«˜ï¼Œä¸é”™</mark>

| ç”²åŸºè‹¯ä¸™èƒº | |
| --- | --- |
| [![Methamphetamine.svg](/æ–‡ä»¶/Methamphetamine.svg)](/æ–‡ä»¶/Methamphetamine.svg) | |
| **åŒ–å­¦å‘½å** | |
| å¸¸ç”¨åç§° | *Methamphetamine, Meth, Crystal, Desoxyn, Speed, Ma, Ice, Glass, Shard, Tina, T, Tweak, Crank, Shabu, Yaba, å†°æ¯’, éº»å¤* |
| å–ä»£åç§° | *N\-Methylamphetamine* |
| ç³»ç»Ÿå‘½å | *N\-Methyl\-1\-phenylpropan\-2\-amine* |
| **åˆ†ç±»æˆå‘˜** | |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)* |
| åŒ–å­¦åˆ†ç±» | *è‹¯ä¸™èƒº (Amphetamine)* |
| **[ç»™è¯æ–¹å¼](/æ–‡æ¡£/home.md)** | |
| è­¦å‘Š | **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€æ–°é™ˆä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚è¯·å‚é˜…[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/home.md)ã€‚ |

### å‰‚é‡ä¸æ—¶é•¿æ¦‚è§ˆ

ä»¥ä¸‹æ•°æ®æ”¶é›†è‡ªç”¨æˆ·æŠ¥å‘Šå’Œèµ„æºï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ï¼Œå¹¶éåŒ»ç–—å»ºè®®ã€‚**è¯·åŠ¡å¿…è°¨æ…ä½¿ç”¨ã€‚**

#### â‡£ æŠ½å¸/æ°”åŒ– (Smoked)

| å‰‚é‡ (Dosage) | é‡ | | æ—¶é•¿ (Duration) | æ—¶é—´ |
| --- | --- | --- | --- | --- |
| **[é˜ˆå€¼](/æ–‡æ¡£/home.md)** | < 5 mg | | **[æ€»æ—¶é•¿](/æ–‡æ¡£/home.md)** | 2 \- 6 å°æ—¶ (éç»å¸¸ä½¿ç”¨è€…å¯è¾¾12å°æ—¶) |
| **[è½»å¾®](/æ–‡æ¡£/home.md)** | 5 \- 10 mg | | **[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/home.md)** | 7 \- 10 ç§’ |
| **[ä¸­ç­‰](/æ–‡æ¡£/home.md)** | 10 \- 20 mg | | **[è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/home.md)** | 5 \- 10 ç§’ |
| **[å¼ºçƒˆ](/æ–‡æ¡£/home.md)** | 20 \- 60 mg | | **[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/home.md)** | 1 \- 3 å°æ—¶ |
| **[ä¸¥é‡](/æ–‡æ¡£/home.md)** | 60 mg \+ | | **[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/home.md)** | 1 \- 3 å°æ—¶ |
| **ç”Ÿç‰©åˆ©ç”¨åº¦** | >90% | | **[è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/home.md)** | 2 \- 24 å°æ—¶ |

#### â‡£ å£æœ (Oral)

| å‰‚é‡ (Dosage) | é‡ | | æ—¶é•¿ (Duration) | æ—¶é—´ |
| --- | --- | --- | --- | --- |
| **[é˜ˆå€¼](/æ–‡æ¡£/home.md)** | < 5 mg | | **[æ€»æ—¶é•¿](/æ–‡æ¡£/home.md)** | 8 \- 12 å°æ—¶ (éç»å¸¸ä½¿ç”¨è€…å¯è¾¾24å°æ—¶) |
| **[è½»å¾®](/æ–‡æ¡£/home.md)** | 5 \- 10 mg | | **[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/home.md)** | 15 \- 45 åˆ†é’Ÿ |
| **[ä¸­ç­‰](/æ–‡æ¡£/home.md)** | 10 \- 25 mg | | **[è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/home.md)** | 1 \- 3 å°æ—¶ |
| **[å¼ºçƒˆ](/æ–‡æ¡£/home.md)** | 25 \- 50 mg | | **[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/home.md)** | 3 \- 5 å°æ—¶ |
| **[ä¸¥é‡](/æ–‡æ¡£/home.md)** | 50 mg \+ | | **[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/home.md)** | 3 \- 4 å°æ—¶ |
| **ç”Ÿç‰©åˆ©ç”¨åº¦** | ~70%[\[1\]](#cite_note-Rau2016-1) | | **[è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/home.md)** | 12 \- 24 å°æ—¶ |

#### â‡£ é¼»å¸ (Insufflated)

| å‰‚é‡ (Dosage) | é‡ | | æ—¶é•¿ (Duration) | æ—¶é—´ |
| --- | --- | --- | --- | --- |
| **[é˜ˆå€¼](/æ–‡æ¡£/home.md)** | < 5 mg | | **[æ€»æ—¶é•¿](/æ–‡æ¡£/home.md)** | 4 \- 7 å°æ—¶ (éç»å¸¸ä½¿ç”¨è€…å¯è¾¾12å°æ—¶) |
| **[è½»å¾®](/æ–‡æ¡£/home.md)** | 5 \- 10 mg | | **[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/home.md)** | 3 \- 5 åˆ†é’Ÿ |
| **[ä¸­ç­‰](/æ–‡æ¡£/home.md)** | 10 \- 30 mg | | **[è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/home.md)** | 3 \- 5 åˆ†é’Ÿ |
| **[å¼ºçƒˆ](/æ–‡æ¡£/home.md)** | 30 \- 60 mg | | **[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/home.md)** | 1.5 \- 3 å°æ—¶ |
| **[ä¸¥é‡](/æ–‡æ¡£/home.md)** | 60 mg \+ | | **[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/home.md)** | 2 \- 4 å°æ—¶ |
| **ç”Ÿç‰©åˆ©ç”¨åº¦** | >90% | | **[è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/home.md)** | 6 \- 24 å°æ—¶ |

#### â‡£ ç›´è‚ ç»™è¯ (Rectal)

| å‰‚é‡ (Dosage) | é‡ | | æ—¶é•¿ (Duration) | æ—¶é—´ |
| --- | --- | --- | --- | --- |
| **[é˜ˆå€¼](/æ–‡æ¡£/home.md)** | < 5 mg | | **[æ€»æ—¶é•¿](/æ–‡æ¡£/home.md)** | 6 \- 10 å°æ—¶ (éç»å¸¸ä½¿ç”¨è€…å¯è¾¾18å°æ—¶) |
| **[è½»å¾®](/æ–‡æ¡£/home.md)** | 5 \- 10 mg | | **[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/home.md)** | 5 \- 15 åˆ†é’Ÿ |
| **[ä¸­ç­‰](/æ–‡æ¡£/home.md)** | 10 \- 30 mg | | **[è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/home.md)** | 3 \- 5 åˆ†é’Ÿ |
| **[å¼ºçƒˆ](/æ–‡æ¡£/home.md)** | 30 \- 40 mg | | **[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/home.md)** | 2 \- 4 å°æ—¶ |
| **[ä¸¥é‡](/æ–‡æ¡£/home.md)** | 40 mg \+ | | **[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/home.md)** | 3 \- 5 å°æ—¶ |
| **ç”Ÿç‰©åˆ©ç”¨åº¦** | ~99%[\[2\]](#cite_note-Methamphetamine_.7C_City_Vision-2) | | **[è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/home.md)** | 12 \- 24 å°æ—¶ |

#### â‡£ é™è„‰æ³¨å°„ (Intravenous)

| å‰‚é‡ (Dosage) | é‡ | | æ—¶é•¿ (Duration) | æ—¶é—´ |
| --- | --- | --- | --- | --- |
| **[é˜ˆå€¼](/æ–‡æ¡£/home.md)** | < 5 mg | | **[æ€»æ—¶é•¿](/æ–‡æ¡£/home.md)** | 4 \- 8 å°æ—¶ (éç»å¸¸ä½¿ç”¨è€…å¯è¾¾18å°æ—¶) |
| **[è½»å¾®](/æ–‡æ¡£/home.md)** | 5 \- 10 mg | | **[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/home.md)** | 15 \- 30 ç§’ |
| **[ä¸­ç­‰](/æ–‡æ¡£/home.md)** | 10 \- 30 mg | | **[è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/home.md)** | 1 \- 2 åˆ†é’Ÿ |
| **[å¼ºçƒˆ](/æ–‡æ¡£/home.md)** | 30 \- 40 mg | | **[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/home.md)** | 1 \- 3 å°æ—¶ |
| **[ä¸¥é‡](/æ–‡æ¡£/home.md)** | 40 mg \+ | | **[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/home.md)** | 3 \- 4 å°æ—¶ |
| **ç”Ÿç‰©åˆ©ç”¨åº¦** | ~100%[\[1\]](#cite_note-Rau2016-1) | | **[è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/home.md)** | 12 \- 24 å°æ—¶ |

| [è¯ç‰©è”ç”¨](#Dangerous_interactions) | |
| --- | --- |
| é…’ç²¾ (Alcohol) | âš ï¸ æ…ç”¨ |
| GHB | ğŸ’” å±é™© |
| GBL | ğŸ’” å±é™© |
| é˜¿ç‰‡ç±»è¯ç‰© (Opioids) | ğŸ’” å±é™© |
| å¯å¡å›  (Cocaine) | ğŸ’” å±é™© |
| å¤§éº» (Cannabis) | âš ï¸ æ…ç”¨ |
| å’–å•¡å›  (Caffeine) | âš ï¸ æ…ç”¨ |
| æ°¯èƒºé…® (Ketamine) | âš ï¸ æ…ç”¨ |
| Methoxetamine | ğŸ’” å±é™© |
| è¿·å¹»å‰‚ (Psychedelics) | âš ï¸ æ…ç”¨ |
| å³ç¾æ²™èŠ¬ (DXM) | ğŸ’” å±é™© |
| PCP | ğŸ’” å±é™© |
| 25x\-NBOMe | ğŸ’” å±é™© |
| 2C\-T\-x | ğŸ’” å±é™© |
| 5\-MeO\-xxT | ğŸ’” å±é™© |
| DOx | ğŸ’” å±é™© |
| Tramadol | ğŸ’” å±é™© |
| aMT | ğŸ’” å±é™© |
| MAOIs | â›” ç¦æ­¢ |

**N-ç”²åŸºè‹¯ä¸™èƒº**ï¼ˆ**N-Methylamphetamine**ï¼Œä¹Ÿç§°ä¸º **Methamphetamine**ã€**Ma**ã€**Meth**ã€**Glass**ã€**Ice**ã€**Shard**ã€**Crank**ã€**Tina**ã€**T**ã€**Tweak**ã€**Yaba**ã€**Shabu** ä»¥åŠ **Crystal**[\[3\]](#cite_note-erowid-3)ï¼Œä¸­æ–‡ä¿—ç§°**å†°æ¯’**ã€**éº»å¤**ç­‰ï¼‰æ˜¯ä¸€ç§è‹¯ä¸™èƒºç±»çš„å…¸å‹[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç‰©è´¨ã€‚å®ƒåœ¨ç»“æ„ä¸Šä¸è‹¯ä¸™èƒºï¼ˆAmphetamineï¼‰ç›¸å…³ï¼Œä½†ç”±äºå…¶è¾ƒé«˜çš„è„‚æº¶æ€§ï¼Œå®ƒèƒ½æ›´å¿«åœ°ç©¿è¿‡è¡€è„‘å±éšœã€‚[\[4\]](#cite_note-Barr2006-4) å®ƒé€šè¿‡å¢åŠ å¤§è„‘ä¸­[ç¥ç»é€’è´¨](/wiki/Neurotransmitters)è¡€æ¸…ç´ ã€å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ çš„æ°´å¹³äº§ç”Ÿä½œç”¨ã€‚

ç”²åŸºè‹¯ä¸™èƒºæœ€åˆç”±æ—¥æœ¬åŒ–å­¦å®¶é•¿äº•é•¿ä¹‰äº 1893 å¹´ä»[éº»é»„ç¢±](/wiki/Ephedrine)åˆæˆè€Œæ¥ã€‚[\[5\]](#cite_note-5) ä¸[æµ·æ´›å› ](/wiki/Heroin)å’Œ[å¯å¡å› ](/wiki/Cocaine)ä¸€æ ·ï¼Œå®ƒä½œä¸ºä¸€ç§å±é™©ä¸”é«˜åº¦æˆç˜¾çš„â€œè¡—å¤´æ¯’å“â€è€Œè‡­åæ˜­è‘—ã€‚[\[6\]](#cite_note-6)

[ä¸»è§‚æ•ˆåº”](/wiki/Subjective_effects)åŒ…æ‹¬[åŠ¨æœºå¢å¼º](/wiki/Motivation_enhancement)ã€[è€åŠ›å¢å¼º](/è¯æ•ˆ/è€åŠ›å¢å¼º.md)ã€[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)ã€[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)å’Œ[æ¬£å¿«æ„Ÿ](/wiki/Euphoria)ã€‚é•¿æœŸå¤§å‰‚é‡ä½¿ç”¨ä¼šå¯¼è‡´[ç„¦è™‘](/wiki/Anxiety)ã€[åæ‰§](/wiki/Paranoia)ã€[å¦„æƒ³](/wiki/Delusions)ã€[æ€ç»´è§£ä½“](/wiki/Thought_disorganization)ã€[ç²¾ç¥ç—…](/wiki/Psychosis)å’Œæš´åŠ›è¡Œä¸ºã€‚å®ƒä¸[å¼ºè¿«æ€§é‡å¤ç”¨è¯](/wiki/Compulsive_redosing)å¯†åˆ‡ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯å½“é€šè¿‡[æ°”åŒ–](/wiki/Vaporized)ï¼ˆâ€œæŠ½å¸â€ï¼‰æˆ–[æ³¨å°„](/wiki/Injected)æ–¹å¼ä½¿ç”¨æ—¶ï¼Œå› ä¸ºè¿™ä¼šåœ¨ç»™è¯åˆæœŸç»™ä½¿ç”¨è€…å¸¦æ¥å‹å€’æ€§çš„[æ¬£å¿«](/wiki/Euphoric)å†²å‡»æ„Ÿã€‚

ç ”ç©¶è¡¨æ˜ç”²åŸºè‹¯ä¸™èƒºå…·æœ‰æé«˜çš„æ»¥ç”¨å’Œæˆç˜¾æ½œåŠ›ï¼›ç”±äºå…¶äº§ç”Ÿçš„å¼ºçƒˆæ¬£å¿«æ„Ÿï¼Œå®ƒè¢«å¹¿æ³›è®¤ä¸ºæ˜¯æˆç˜¾æ€§æœ€å¼ºçš„ç‰©è´¨ä¹‹ä¸€ã€‚æ­¤å¤–ï¼Œä¸æ²»ç–—å‰‚é‡çš„è‹¯ä¸™èƒºä¸åŒï¼Œä¸­ç­‰åˆ°ä¸¥é‡[å¨±ä¹å‰‚é‡](/wiki/Recreational_drug_use)çš„ç”²åŸºè‹¯ä¸™èƒºè¢«è®¤ä¸ºå¯¹äººç±»å…·æœ‰ç›´æ¥çš„[ç¥ç»æ¯’æ€§](/wiki/Neurotoxicity)ï¼Œä¼šæŸå®³ä¸­æ¢ç¥ç»ç³»ç»Ÿå†…çš„[å¤šå·´èƒº](/wiki/Dopamine)å’Œ[è¡€æ¸…ç´ ](/wiki/Serotonin) [ç¥ç»å…ƒ](/wiki/Neurons)ã€‚åœ¨éäººç±»å“ºä¹³åŠ¨ç‰©ä¸­ï¼Œå·²çŸ¥ä¼šå‘ç”Ÿå•èƒºèƒ½ç¥ç»æœ«æ¢¢çš„é€€åŒ–å’Œç¥ç»å…ƒå‡‹äº¡ï¼ˆç»†èƒæ­»äº¡ï¼‰ã€‚[\[7\]](#cite_note-7) åœ¨äººç±»ä¸­ï¼Œè¿™ç§å½±å“ä¹Ÿå…·æœ‰[ç¥ç»æ¯’æ€§](/wiki/Neurotoxicity)ã€‚[\[8\]](#cite_note-8) å®ƒè¿˜æ˜¾ç¤ºå‡ºå¿ƒè„æ¯’æ€§ï¼ŒåŒ…æ‹¬[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md)ä»¥åŠä¸­é£å’Œå¿ƒè„ç—…å‘ä½œé£é™©å¢åŠ ã€‚

å¦‚æœä½¿ç”¨è¯¥ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/home.md)ã€‚

[![](https://psychonautwiki.org/w/thumb.php?f=Crystal_Meth.jpg&width=250)](/æ–‡ä»¶/Crystal_Meth.jpg)

çº¯ç›é…¸ç”²åŸºè‹¯ä¸™èƒºçš„â€œç¢ç‰‡â€ï¼Œé€šå¸¸è¢«ç§°ä¸ºâ€œæ°´æ™¶â€æˆ–â€œå†°æ¯’â€ã€‚

ç›®å½•
--------

* [1 å†å²ä¸æ–‡åŒ–](#History_and_culture)
* [2 åŒ–å­¦](#Chemistry)
    + [2.1 ç«‹ä½“å¼‚æ„ä½“](#Stereoisomers)
* [3 è¯ç†å­¦](#Pharmacology)
* [4 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [4.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [4.2 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        - [4.2.1 æŠ‘åˆ¶](#Suppressions)
        - [4.2.2 æ‰­æ›²](#Distortions)
        - [4.2.3 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
    + [4.3 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    + [4.4 **è¯æ•ˆæ®‹ä½™**](#After_effects)
    + [4.5 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [5 æ¯’æ€§ä¸å±å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [5.1 ç¥ç»æ¯’æ€§](#Neurotoxicity)
    + [5.2 ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›](#Dependence_and_abuse_potential)
    + [5.3 ç²¾ç¥ç—…](#Psychosis)
    + [5.4 è¿‡é‡](#Overdose)
        - [5.4.1 ç´§æ€¥æ²»ç–—](#Emergency_treatment)
    + [5.5 ä¼¤å®³å‡å°‘](#Harm_reduction)
    + [5.6 å±é™©çš„è¯ç‰©è”ç”¨](#Dangerous_interactions)
* [6 æ³•å¾‹åœ°ä½](#Legal_status)
* [7 å¦è§](#See_also)
* [8 å¤–éƒ¨é“¾æ¥](#External_links)
* [9 å‚è€ƒæ–‡çŒ®](#References)

å†å²ä¸æ–‡åŒ–
-------------------

è‹¯ä¸™èƒºäº 1887 å¹´ç”±ç½—é©¬å°¼äºšåŒ–å­¦å®¶ LazÄƒr Edeleanu åœ¨å¾·å›½é¦–æ¬¡åˆæˆï¼Œå¹¶å‘½åä¸ºè‹¯åŸºå¼‚ä¸™èƒºã€‚[\[9\]](#cite_note-9) æ­¤åä¸ä¹…ï¼Œæ—¥æœ¬åŒ–å­¦å®¶é•¿äº•é•¿ä¹‰äº 1893 å¹´ä»éº»é»„ç¢±åˆæˆäº†ç”²åŸºè‹¯ä¸™èƒºã€‚[\[10\]](#cite_note-10) ç›´åˆ° 1934 å¹´ï¼Œè¿™ä¸¤ç§è¯ç‰©éƒ½æ²¡æœ‰è¯ç†ç”¨é€”ï¼Œå½“æ—¶ Smith, Kline, and French å¼€å§‹ä»¥ Benzedrine çš„å•†å“åé”€å”®è‹¯ä¸™èƒºå¸å…¥å‰‚ä½œä¸ºå‡å……è¡€å‰‚ã€‚[\[11\]](#cite_note-11) åœ¨ç¬¬äºŒæ¬¡ä¸–ç•Œå¤§æˆ˜æœŸé—´ï¼Œç›Ÿå†›å’Œè½´å¿ƒå›½å†›é˜Ÿéƒ½å¹¿æ³›ä½¿ç”¨è‹¯ä¸™èƒºå’Œç”²åŸºè‹¯ä¸™èƒºï¼Œä»¥åˆ©ç”¨å…¶å…´å¥‹å’Œå¢å¼ºä½“èƒ½çš„ä½œç”¨ã€‚[\[12\]](#cite_note-:0-12)[\[13\]](#cite_note-13)

æœ€ç»ˆï¼Œéšç€è¿™äº›è¯ç‰©çš„æˆç˜¾æ€§ä¸ºäººæ‰€çŸ¥ï¼Œå„å›½æ”¿åºœå¼€å§‹ä¸¥æ ¼æ§åˆ¶å…¶é”€å”®ã€‚[\[14\]](#cite_note-14) ä¾‹å¦‚ï¼Œ1970 å¹´åœ¨ç¾å›½ï¼Œç”²åŸºè‹¯ä¸™èƒºå’Œè‹¯ä¸™èƒºæ ¹æ®ã€Šå—æ§ç‰©è´¨æ³•ã€‹æˆä¸ºé™„è¡¨ II ç®¡åˆ¶ç‰©è´¨ã€‚[\[15\]](#cite_note-15)

å°½ç®¡æ”¿åºœç®¡åˆ¶ä¸¥æ ¼ï¼Œè‹¯ä¸™èƒºå’Œç”²åŸºè‹¯ä¸™èƒºä»ç„¶è¢«ä¸åŒèƒŒæ™¯çš„äººå‡ºäºå„ç§ç›®çš„åˆæ³•æˆ–éæ³•ä½¿ç”¨ã€‚[\[16\]](#cite_note-16)[\[17\]](#cite_note-17)[\[18\]](#cite_note-18)[\[19\]](#cite_note-19) ç”±äºè¿™äº›è¯ç‰©æœ‰ç€åºå¤§çš„åœ°ä¸‹å¸‚åœºï¼Œå®ƒä»¬ç»å¸¸ç”±åœ°ä¸‹åŒ–å­¦å®¶éæ³•åˆæˆã€è´©è¿å¹¶åœ¨é»‘å¸‚ä¸Šå‡ºå”®ã€‚[\[20\]](#cite_note-20) æ ¹æ®è¯ç‰©å’Œå‰ä½“è¯ç‰©çš„ç¼‰è·é‡ï¼Œéæ³•è‹¯ä¸™èƒºçš„ç”Ÿäº§å’Œè´©è¿è¿œä¸å¦‚ç”²åŸºè‹¯ä¸™èƒºæ™®éã€‚

ç›é…¸ç”²åŸºè‹¯ä¸™èƒºå·²è·å¾—ç¾å›½é£Ÿå“å’Œè¯ç‰©ç®¡ç†å±€ (USFDA) çš„æ‰¹å‡†ï¼Œå•†å“åä¸ºâ€œDesoxynâ€ã€‚[\[21\]](#cite_note-21) ç„¶è€Œï¼Œç”±äºå…¶æ»¥ç”¨æ½œåŠ›ï¼Œå®ƒå¾ˆå°‘è¢«å¤„æ–¹ï¼Œé€šå¸¸ä»…ä¿ç•™ç”¨äºæ‰€æœ‰å…¶ä»–æ²»ç–—æ–¹æ¡ˆå‡å·²ç”¨å°½çš„ä¸¥é‡è‚¥èƒ–æˆ– ADHD ç—…ä¾‹ã€‚

åŒ–å­¦
---------

ç”²åŸºè‹¯ä¸™èƒºï¼Œæˆ– N-ç”²åŸºè‹¯ä¸™èƒºï¼Œæ˜¯[è‹¯ä¸™èƒº](/wiki/Amphetamine)å®¶æ—çš„ä¸€ç§åˆæˆåˆ†å­ã€‚è‹¯ä¸™èƒºç±»åˆ†å­åŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œå…¶ç‰¹å¾æ˜¯è‹¯ç¯é€šè¿‡ä¹™åŸºé“¾ç»“åˆåˆ°ä¸€ä¸ªæ°¨åŸº (NH2) åŸºå›¢ä¸Šï¼Œå¹¶åœ¨ RÎ± å¤„æœ‰ä¸€ä¸ªé¢å¤–çš„ç”²åŸºå–ä»£ã€‚è‹¯ä¸™èƒºæ˜¯ Î±-ç”²åŸºåŒ–è‹¯ä¹™èƒºã€‚ç”²åŸºè‹¯ä¸™èƒºåœ¨ RN å¤„åŒ…å«ä¸€ä¸ªé¢å¤–çš„ç”²åŸºå–ä»£ï¼Œè¿™ä¸€å–ä»£ä¹Ÿå­˜åœ¨äº [MDMA](/wiki/MDMA)ã€[ç”²å¡è¥¿é…®](/wiki/Methcathinone)å’Œ[ç”²æ°§éº»é»„é…®](/wiki/Mephedrone)ä¸­ã€‚

### ç«‹ä½“å¼‚æ„ä½“

ç”²åŸºè‹¯ä¸™èƒºä»¥ä¸¤ç§[å¯¹æ˜ å¼‚æ„ä½“](/wiki/Enantiomers)å½¢å¼å­˜åœ¨ï¼šå³æ—‹å’Œå·¦æ—‹ã€‚å³æ—‹ç”²åŸºè‹¯ä¸™èƒºï¼ˆä¹Ÿç§°ä¸º d-ç”²åŸºè‹¯ä¸™èƒºï¼‰æ˜¯ä¸€ç§æ¯”å·¦æ—‹ç”²åŸºè‹¯ä¸™èƒºæ›´å¼ºçš„ä¸­æ¢ç¥ç»ç³»ç»Ÿ (CNS) å…´å¥‹å‰‚ï¼›ç„¶è€Œï¼Œä¸¤è€…åœ¨æ»¥ç”¨æ—¶éƒ½è¢«è®¤ä¸ºå…·æœ‰ä¾èµ–æ€§å’Œæˆç˜¾æ€§ï¼Œå¹¶ä¸”åœ¨å¤§é‡å¨±ä¹å‰‚é‡ä¸‹èƒ½å¤Ÿäº§ç”Ÿç±»ä¼¼çš„æ¯’æ€§ç—‡çŠ¶ã€‚

è¯ç†å­¦
------------

ç”²åŸºè‹¯ä¸™èƒºä¸»è¦é€šè¿‡ä½œä¸º[å¤šå·´èƒº](/wiki/Dopamine)ã€[å»ç”²è‚¾ä¸Šè…ºç´ ](/wiki/Norepinephrine)å’Œ[è¡€æ¸…ç´ ](/wiki/Serotonin)ç­‰[ç¥ç»é€’è´¨](/wiki/Neurotransmitters)çš„[é‡Šæ”¾å‰‚](/wiki/Releasing_agent)æ¥å½±å“ä¸­æ¢ç¥ç»ç³»ç»Ÿ (CNS)ã€‚[\[22\]](#cite_note-22) å®ƒè¿˜ä½œä¸ºæŸäº›è½¬è¿ä½“ç¥ç»å…ƒçš„[å†æ‘„å–æŠ‘åˆ¶å‰‚](/wiki/Reuptake_inhibitor)ï¼Œä»è€Œå°†å»ç”²è‚¾ä¸Šè…ºç´ ç­‰ç¥ç»é€’è´¨ä¿æŒåœ¨çªè§¦ä¸­ã€‚[\[23\]](#cite_note-23) å†°æ¯’è¿˜ä½œä¸ºæŸäº›è½¬è¿ä½“ç¥ç»å…ƒçš„åå‘è½¬è¿ä½“ï¼Œé€šè¿‡è¿«ä½¿ç¥ç»é€’è´¨ç¦»å¼€å…¶å‚¨å­˜å›Šæ³¡å¹¶ä½¿å¤šå·´èƒºè½¬è¿ä½“åå‘å·¥ä½œï¼Œå°†å®ƒä»¬æ’å‡ºåˆ°çªè§¦é—´éš™ï¼Œä»è€Œå¢åŠ å•èƒºæ°´å¹³ã€‚[\[24\]](#cite_note-24)[\[25\]](#cite_note-25) ç”²åŸºè‹¯ä¸™èƒºå·²çŸ¥å¢åŠ å•èƒºæ°´å¹³çš„å…¶ä»–æœºåˆ¶åŒ…æ‹¬ï¼š

*   å‡å°‘ç»†èƒè¡¨é¢å¤šå·´èƒºè½¬è¿ä½“çš„è¡¨è¾¾ï¼Œè¿™å…·æœ‰ä¸ä¸Šè¿°ç›¸åŒçš„æ•ˆæœã€‚
*   é€šè¿‡æŠ‘åˆ¶[å•èƒºæ°§åŒ–é…¶](/wiki/MAOI) (MAO) çš„æ´»æ€§æ¥å¢åŠ èƒè´¨å•èƒºæ°´å¹³ã€‚
*   å¢åŠ [å¤šå·´èƒº](/wiki/Dopamine)åˆæˆé…¶é…ªæ°¨é…¸ç¾ŸåŒ–é…¶ (TH) çš„æ´»æ€§å’Œè¡¨è¾¾ã€‚

é™¤äº†é‡Šæ”¾å¤§é‡çš„å•èƒºå¤–ï¼Œç”²åŸºè‹¯ä¸™èƒºè¿˜å…·æœ‰é«˜è„‚æº¶æ€§ï¼Œè¿™å¯¼è‡´è¯ç‰©èƒ½å¤Ÿç›¸å¯¹è¾ƒå¿«åœ°ç©¿è¿‡è¡€è„‘å±éšœï¼Œä¸å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç›¸æ¯”èµ·æ•ˆè¿…é€Ÿã€‚[\[4\]](#cite_note-Barr2006-4) æ‰€æœ‰è¿™äº›éƒ½ä¼šå¯¼è‡´å¥–èµæ„Ÿã€æ¬£å¿«æ„Ÿå’Œåˆºæ¿€æ„Ÿï¼Œä»¥åŠéšä¹‹è€Œæ¥çš„ä¸æ„‰å¿«çš„è¯æ•ˆæ¶ˆé€€æœŸã€‚

ä¸»è§‚æ•ˆåº”
------------------

***å…è´£å£°æ˜ï¼š**ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/wiki/Subjective_effect_index) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](/wiki/PsychonautWiki) [è´¡çŒ®è€…](/wiki/Special:TopUsers) ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…è¿™äº›å†…å®¹ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡é«˜å‰‚é‡æ›´å®¹æ˜“è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**çš„å¯èƒ½æ€§éšç€å‰‚é‡çš„å¢åŠ è€Œå¢åŠ ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

*   **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)** - å°±å…¶å¯¹ä½¿ç”¨è€…ä½“èƒ½æ°´å¹³çš„å½±å“è€Œè¨€ï¼Œç”²åŸºè‹¯ä¸™èƒºé€šå¸¸è¢«è®¤ä¸ºå…·æœ‰æå¼ºçš„æ´»åŠ›å’Œåˆºæ¿€æ€§ï¼Œå…¶æ–¹å¼ä¸[è‹¯ä¸™èƒº](/wiki/Amphetamine)ç›¸åŒï¼Œä½†å¼ºäº[è«è¾¾éå°¼](/wiki/Modafinil)ã€[å’–å•¡å› ](/wiki/Caffeine)å’Œ[MDMA](/wiki/MDMA)ã€‚å®ƒä¸[MDMA](/wiki/MDMA)å¸¦æ¥çš„åˆºæ¿€ç›¸ä¼¼ä½†åˆä¸åŒï¼Œå®ƒé¼“åŠ±è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ç­‰èº«ä½“æ´»åŠ¨ã€‚ç”²åŸºè‹¯ä¸™èƒºå‘ˆç°çš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºå¼ºåˆ¶æ€§çš„ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œéšç€ä¸‹é¢šç´§å’¬ã€ä¸è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’Œéœ‡åŠ¨å‡ºç°ï¼Œä¿æŒé™æ­¢å˜å¾—å›°éš¾æˆ–ä¸å¯èƒ½ï¼Œå¯¼è‡´å…¨èº«å‰§çƒˆé¢¤æŠ–ã€æ‰‹éƒ¨ä¸ç¨³å’Œæ™®éç¼ºä¹è¿åŠ¨æ§åˆ¶ã€‚
*   **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)** - ä½œä¸ºä¸€ç§å¼ºæ•ˆå…´å¥‹å‰‚ï¼Œç”²åŸºè‹¯ä¸™èƒºèƒ½å¤Ÿäº§ç”Ÿå¼ºçƒˆçš„èº¯ä½“æ¬£å¿«æ„Ÿï¼Œç‰¹åˆ«æ˜¯å½“è¢«[æ°”åŒ–](/wiki/Vaporized)æˆ–[æ³¨å°„](/wiki/Injected)æ—¶ã€‚ç„¶è€Œï¼Œæœ€åˆçš„æ¬£å¿«å†²å‡»å¯èƒ½ä¼šåœ¨ç‰©è´¨å®Œå…¨ä»£è°¢ä¹‹å‰æ¶ˆé€€ï¼Œè¿™ä¼šä¿ƒä½¿å¼ºè¿«æ€§é‡å¤ç”¨è¯ï¼Œä»è€Œäº§ç”Ÿæå…·ç ´åæ€§çš„ç´¯ç§¯æ•ˆåº”ã€‚
*   **[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md)**
*   **[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md)**
*   **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**
*   **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)**
*   **[ä½“å‘³æ”¹å˜](/wiki/Body_odor_alteration)** - ç”²åŸºè‹¯ä¸™èƒºå¯èƒ½ä¼šåœ¨ä½¿ç”¨è€…çš„å°¿æ¶²ã€æ±—æ°´å’Œä¸€èˆ¬èº«ä½“åˆ†æ³Œç‰©ä¸­ç•™ä¸‹éå¸¸ç‹¬ç‰¹çš„æ°”å‘³ã€‚å¤§å¤šæ•°äººè®¤ä¸ºè¿™ç§æ°”å‘³ä»¤äººä¸å¿«ï¼Œä½†å°‘æ•°äººå–œæ¬¢å®ƒå¹¶è§‰å¾—å®ƒéå¸¸ä»¤äººæ„‰æ‚¦ã€‚
*   **[æ”¯æ°”ç®¡æ‰©å¼ ](/è¯æ•ˆ/æ”¯æ°”ç®¡æ‰©å¼ .md)**
*   **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md)**
*   **[å°¿é¢‘](/è¯æ•ˆ/å°¿é¢‘.md)**
*   **[ä½“æ¸©å‡é«˜](/è¯æ•ˆ/ä½“æ¸©å‡é«˜.md)**
*   **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md)**
*   **[è‚Œè‚‰æ”¶ç¼©](/wiki/Muscle_contractions)**
*   **[è‚Œè‚‰ç—‰æŒ›](/è¯æ•ˆ/è‚Œè‚‰ç—‰æŒ›.md)**
*   **[ç¥ç»æ¯’æ€§](/wiki/Neurotoxicity)** -- é•¿æœŸä½¿ç”¨ã€‚
*   **[è€åŠ›å¢å¼º](/è¯æ•ˆ/è€åŠ›å¢å¼º.md)** - è¿™ç§æ•ˆåº”æ¯”ä»»ä½•å…¶ä»–å¸¸ç”¨[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)éƒ½æ›´æ˜¾è‘—ã€‚
*   **[è§¦è§‰å¢å¼º](/wiki/Tactile_enhancement)**
*   **[è§¦è§‰å¹»è§‰](/wiki/Tactile_hallucination)** - é«˜å‰‚é‡å’Œ/æˆ–é•¿æœŸä½¿ç”¨æŸäº›å…´å¥‹å‰‚ï¼ˆå¦‚ç”²åŸºè‹¯ä¸™èƒºå’Œ[å¯å¡å› ](/wiki/Cocaine)ï¼‰ä¼šå¯¼è‡´äº§ç”Ÿè™«å­åœ¨çš®è‚¤è¡¨é¢æˆ–çš®ä¸‹çˆ¬è¡Œçš„å¹»è§‰æ„Ÿè§‰ã€‚è¿™é€šå¸¸è¢«ç§°ä¸º*å¯„ç”Ÿè™«å¦„æƒ³*ï¼Œæˆ–éæ­£å¼åœ°ç§°ä¸ºâ€œå†°æ¯’è¨â€ã€‚
*   **[ç£¨ç‰™](/è¯æ•ˆ/ç£¨ç‰™.md)**
*   **[æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢](/è¯æ•ˆ/æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢.md)**
*   **[è¡€ç®¡æ”¶ç¼©](/wiki/Vasoconstriction)**
*   **[ç³å­”æ‰©å¤§](/è¯æ•ˆ/ç³å­”æ‰©å¤§.md)**
*   **[è§†ç‰©æŒ¯åŠ¨](/è¯æ•ˆ/è§†ç‰©æŒ¯åŠ¨.md)** - åœ¨é«˜å‰‚é‡æˆ–æŸäº›ç»™è¯é€”å¾„ä¸‹ï¼Œäººçš„çœ¼çƒå¯èƒ½ä¼šå¼€å§‹å¿«é€Ÿåœ°æ¥å›æ‘†åŠ¨ï¼Œå¯¼è‡´è§†åŠ›æ¨¡ç³Šå¹¶æš‚æ—¶å¤±ç„¦ã€‚è¿™æ˜¯ä¸€ç§ç§°ä¸º[çœ¼çƒéœ‡é¢¤](http://en.wikipedia.org/wiki/Nystagmus)çš„çŠ¶å†µã€‚
*   **[ç™«ç—«å‘ä½œ](/è¯æ•ˆ/ç™«ç—«å‘ä½œ.md)** - è¿™æ˜¯ä¸€ç§ä¸å¸¸è§çš„æ•ˆåº”ï¼Œä½†åœ¨æ˜“æ„Ÿäººç¾¤ä¸­å¯èƒ½ä¼šå‘ç”Ÿï¼Œå°¤å…¶æ˜¯åœ¨èº«ä½“è´Ÿæ‹…é‡çš„æƒ…å†µä¸‹ï¼Œå¦‚è„±æ°´ã€ç–²åŠ³æˆ–è¥å…»ä¸è‰¯ï¼Œæˆ–é•¿æ—¶é—´æ»¥ç”¨è¯¥ç‰©è´¨æ—¶ã€‚

### **è§†è§‰æ•ˆåº”**

*   ç”²åŸºè‹¯ä¸™èƒºçš„è§†è§‰æ•ˆåº”é€šå¸¸ä¸å¤ªä¸€è‡´ï¼Œåªæœ‰åœ¨é«˜å‰‚é‡ä¸‹æ‰ç¨å¾®æ˜æ˜¾ã€‚å®ƒä»¬åœ¨æŸç§ç¨‹åº¦ä¸Šç±»ä¼¼äº[è°µå¦„å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è°µå¦„å‰‚.md)äº§ç”Ÿçš„è§†è§‰æ•ˆæœï¼Œå¹¶ä¸”åœ¨é»‘æš—åŒºåŸŸæ›´å¸¸è§ã€‚ç”±[æ¸…é†’](/wiki/Wakefulness)å¼•èµ·çš„ä¸¥é‡ç¡çœ å‰¥å¤ºä¼šå¯¼è‡´æ›´å¼ºçƒˆçš„è§†è§‰æ•ˆåº”ï¼Œç”šè‡³[å¹»è§‰](/wiki/External_hallucinations)ã€‚

#### æŠ‘åˆ¶
*   **[å¤è§†](/è¯æ•ˆ/å¤è§†.md)**

#### æ‰­æ›²
*   **[æ¼‚ç§»](/è¯æ•ˆ/æ¼‚ç§».md)** -è¿™ç§æ•ˆåº”é€šå¸¸å¾ˆå¾®å¦™æˆ–å‡ ä¹ä¸æ˜æ˜¾ï¼Œä»…å‘ç”Ÿåœ¨è¾ƒé«˜å‰‚é‡ä¸‹æˆ–ä¸[å¤§éº»](/è¯ç‰©/å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md)ç»“åˆä½¿ç”¨æ—¶ã€‚å½“æŠ½å¸æˆ–é™è„‰æ³¨å°„æ—¶æœ€ä¸ºçªå‡ºï¼Œé€šå¸¸å…·æœ‰[è°µå¦„](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è°µå¦„å‰‚.md)æ€§è´¨ã€‚é€šå¸¸ï¼Œé«˜å‰‚é‡æˆ–é•¿æœŸä½¿ç”¨ä¼šå¯¼è‡´ 1-2 çº§çš„è§†è§‰æ¼‚ç§»ã€‚
*   **[äº®åº¦æ”¹å˜](/è¯æ•ˆ/äº®åº¦æ”¹å˜.md)**

#### å¹»è§‰çŠ¶æ€
*   **[å˜å½¢](/wiki/Transformations)** - è¿™ç§æ•ˆåº”éå¸¸ç½•è§ï¼Œé€šå¸¸ä»…åœ¨ä½¿ç”¨è€…æœç”¨äº†é«˜å‰‚é‡ã€æ­£åœ¨è¯æ•ˆæ¶ˆé€€æˆ–å¼‚å¸¸é•¿æ—¶é—´ä¿æŒæ¸…é†’æ—¶æ‰ä¼šå‘ç”Ÿã€‚å½“å®ƒä»¬ç¡®å®å‘ç”Ÿæ—¶ï¼Œé€šå¸¸éå¸¸è½»å¾®ã€‚

### **è®¤çŸ¥æ•ˆåº”**

*   ç”²åŸºè‹¯ä¸™èƒºçš„è®¤çŸ¥æ•ˆåº”å¯ä»¥åˆ†ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œè¿™äº›éƒ¨åˆ†éšç€å‰‚é‡çš„å¢åŠ è€Œé€æ¸å¢å¼ºã€‚è®¸å¤šäººå°†ç”²åŸºè‹¯ä¸™èƒºçš„æ€»ä½“ç²¾ç¥çŠ¶æ€æè¿°ä¸ºæåº¦ç²¾ç¥[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)ã€[ä¸“æ³¨åŠ›å¢å¼º](/wiki/Focus_enhancement)ã€[è‡ªæˆ‘è†¨èƒ€](/wiki/Ego_inflation)å’Œå¼ºçƒˆçš„æ¬£å¿«æ„Ÿã€‚å®ƒåŒ…å«å¤§é‡å…¸å‹çš„[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)è®¤çŸ¥æ•ˆåº”ã€‚è™½ç„¶å‰¯ä½œç”¨åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹é€šå¸¸å¾ˆè½»å¾®ï¼Œä½†éšç€ç”¨é‡å¢åŠ æˆ–å¹¿æ³›ä½¿ç”¨ï¼Œå‰¯ä½œç”¨è¡¨ç°å‡ºæ¥çš„å¯èƒ½æ€§è¶Šæ¥è¶Šå¤§ã€‚è¿™åœ¨ä½“éªŒçš„æ¶ˆé€€æœŸå°¤å…¶å¦‚æ­¤ã€‚

    æœ€çªå‡ºçš„è®¤çŸ¥æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š

*   **[åˆ†æèƒ½åŠ›å¢å¼º](/wiki/Analysis_enhancement)**
*   **[å¼ºè¿«æ€§é‡å¤ç”¨è¯](/wiki/Compulsive_redosing)**
*   **[è‡ªæˆ‘è†¨èƒ€](/wiki/Ego_inflation)**
*   **[è®¤çŸ¥æ¬£å¿«æ„Ÿ](/wiki/Cognitive_euphoria)** - ä¸å…¶ä»–å¤šå·´èƒºèƒ½å…´å¥‹å‰‚ï¼ˆå¦‚[è‹¯ä¸™èƒº](/wiki/Amphetamine)ç”šè‡³[å¯å¡å› ](/wiki/Cocaine)ï¼‰ç›¸æ¯”ï¼Œè¿™ç§æ•ˆåº”é€šå¸¸éå¸¸å¼ºçƒˆã€‚
*   **[ç§»æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](/wiki/Empathy,_affection_and_sociability_enhancement)** - è¿™ç§æ•ˆåº”æ˜¯è½»å¾®åˆ°ä¸­ç­‰çš„ï¼Œé€šå¸¸åœ¨å‰å‡ æ¬¡ä½¿ç”¨æˆ–äº§ç”Ÿä»»ä½•å½¢å¼çš„è€å—æ€§åæ¶ˆå¤±ã€‚
*   **[ä¸“æ³¨åŠ›å¢å¼º](/wiki/Focus_enhancement)** - è¿™ç§æˆåˆ†åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºæ›´é«˜çš„å‰‚é‡é€šå¸¸ä¼šæŸå®³æ³¨æ„åŠ›ã€‚
*   **[æ²‰æµ¸æ„Ÿå¢å¼º](/wiki/Immersion_enhancement)**
*   **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)**
*   **[éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º](/wiki/Increased_music_appreciation)**
*   **[è®°å¿†åŠ›å¢å¼º](/wiki/Memory_enhancement)**
*   **[åŠ¨æœºå¢å¼º](/wiki/Motivation_enhancement)**
*   **[æ€ç»´åŠ é€Ÿ](/wiki/Thought_acceleration)**
*   **[æ€ç»´ç»„ç»‡](/wiki/Thought_organization)**
*   **[æ—¶é—´å‹ç¼©](/wiki/Time_distortion)** - è¿™å¯ä»¥æè¿°ä¸ºä½“éªŒåˆ°æ—¶é—´åŠ é€Ÿï¼Œæ¯”æ¸…é†’æ—¶è¿‡å¾—å¿«å¾—å¤šã€‚
*   **[æ¸…é†’](/wiki/Wakefulness)**

### **è¯æ•ˆæ®‹ä½™**

*   åœ¨[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ä½“éªŒçš„[è¯æ•ˆè¤ªå»](/wiki/Offset)æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ï¼Œä¸[è¯æ•ˆè¾¾å³°](/wiki/Peak)æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ç›¸æ¯”ï¼Œé€šå¸¸æ„Ÿè§‰æ¶ˆæå’Œä¸èˆ’æœã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œcomedownâ€ï¼Œæ˜¯å› ä¸º[ç¥ç»é€’è´¨](/wiki/Neurotransmitter)è€—å°½è€Œå‘ç”Ÿçš„ã€‚å…¶æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š
    *   **[ç„¦è™‘](/wiki/Anxiety)**
    *   **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)**
    *   **[è®¤çŸ¥ç–²åŠ³](/wiki/Cognitive_fatigue)**
    *   **[æŠ‘éƒ](/wiki/Depression)**
    *   **[æ˜“æ€’](/wiki/Irritability)**
    *   **[åŠ¨æœºæŠ‘åˆ¶](/wiki/Motivation_suppression)**
    *   **[ç¡çœ ç˜«ç—ª](/wiki/Sleep_paralysis)** - ä¸€äº›ä½¿ç”¨è€…æ³¨æ„åˆ°åœ¨æœç”¨ç”²åŸºè‹¯ä¸™èƒºåä¼šå‡ºç°ç¡çœ ç˜«ç—ªã€‚
    *   **[è‡ªæ€æ„å¿µ](/wiki/Suicidal_ideation)**
    *   **[æ€ç»´å‡é€Ÿ](/wiki/Thought_deceleration)**
    *   **[ç²¾ç¥ç—…](/wiki/Psychosis)**
    *   **[æ¸…é†’](/wiki/Wakefulness)** - ä¸ä»»ä½•å…¶ä»–å¸¸ç”¨[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ç›¸æ¯”ï¼Œè¿™ç§ç‰¹å®šçš„åæ•ˆæ›´ä¸ºæ˜æ˜¾ã€‚

### ä½“éªŒæŠ¥å‘Š

ç›®å‰æˆ‘ä»¬çš„[ä½“éªŒç´¢å¼•](/wiki/Experience_index)ä¸­æœ‰ 2 ç¯‡å…³äºè¯¥ç‰©è´¨æ•ˆåº”çš„ä½“éªŒæŠ¥å‘Šã€‚æ‚¨ä¹Ÿå¯ä»¥ä½¿ç”¨ç›¸åŒçš„é“¾æ¥æäº¤æ‚¨è‡ªå·±çš„ä½“éªŒæŠ¥å‘Šã€‚

*   [Experience:35mg Dextromethamphetamine \+ 305mg 3\-Methylmethcathinone \+ 20mg 2C\-B \- destroying myself before rebuilding](/wiki/Experience:35mg_Dextromethamphetamine_%2B_305mg_3-Methylmethcathinone_%2B_20mg_2C-B_-_destroying_myself_before_rebuilding "Experience:35mg Dextromethamphetamine + 305mg 3-Methylmethcathinone + 20mg 2C-B - destroying myself before rebuilding")
*   [Experience:Methamphetamine (20\-40 mg insufflated) \+ cannabis \- Hallucinatory Overdose](/wiki/Experience:Methamphetamine_(20-40_mg_insufflated)_%2B_cannabis_-_Hallucinatory_Overdose "Experience:Methamphetamine (20-40 mg insufflated) + cannabis - Hallucinatory Overdose")

æ¯’æ€§ä¸å±å®³æ½œåŠ›
---------------------------

[![](https://upload.wikimedia.org/wikipedia/commons/thumb/2/2c/HarmCausedByDrugsTable.svg/langen-gb-500px-HarmCausedByDrugsTable.svg.png)](/æ–‡ä»¶/HarmCausedByDrugsTable.svg)

2010 å¹´ ISCD ç ”ç©¶çš„è¡¨æ ¼ï¼Œæ ¹æ®è¯ç‰©å±å®³ä¸“å®¶çš„é™ˆè¿°å¯¹å„ç§è¯ç‰©ï¼ˆåˆæ³•å’Œéæ³•ï¼‰è¿›è¡Œæ’åã€‚ç”²åŸºè‹¯ä¸™èƒºè¢«å‘ç°æ˜¯æ€»ä½“ä¸Šç¬¬å››å±é™©çš„è¯ç‰©ã€‚[\[26\]](#cite_note-Nutt_2010-26)

### ç¥ç»æ¯’æ€§

æœ‰è¯æ®è¡¨æ˜ï¼Œé•¿æœŸä½¿ç”¨ç”²åŸºè‹¯ä¸™èƒºä¼šå¯¹äººç±»é€ æˆè„‘æŸä¼¤ï¼›è¿™ç§æŸä¼¤åŒ…æ‹¬å¤§è„‘ç»“æ„å’ŒåŠŸèƒ½çš„ä¸è‰¯å˜åŒ–ï¼Œä¾‹å¦‚å‡ ä¸ªå¤§è„‘åŒºåŸŸç°è´¨ä½“ç§¯çš„å‡å°‘å’Œä»£è°¢å®Œæ•´æ€§æ ‡å¿—ç‰©çš„ä¸è‰¯å˜åŒ–ã€‚[\[27\]](#cite_note-27)

ä¸[è‹¯ä¸™èƒº](/wiki/Amphetamine)ä¸åŒï¼Œç”²åŸºè‹¯ä¸™èƒºå¯¹[å¤šå·´èƒº](/wiki/Dopamine)ç¥ç»å…ƒå…·æœ‰ç›´æ¥çš„ç¥ç»æ¯’æ€§ã€‚[\[28\]](#cite_note-Nestler2009-28) æ­¤å¤–ï¼Œç”±äºè¿‡åº¦çš„çªè§¦å‰å¤šå·´èƒºè‡ªåŠ¨æ°§åŒ–ï¼ˆä¸€ç§ç¥ç»æ¯’æ€§æœºåˆ¶ï¼‰ï¼Œæ»¥ç”¨ç”²åŸºè‹¯ä¸™èƒºä¸å¸•é‡‘æ£®ç—…é£é™©å¢åŠ æœ‰å…³ã€‚[\[29\]](#cite_note-Cruickshank2009-29)[\[30\]](#cite_note-30)[\[31\]](#cite_note-31)[\[32\]](#cite_note-32) ä¸å¯¹å¤šå·´èƒºç³»ç»Ÿçš„ç¥ç»æ¯’æ€§ä½œç”¨ç±»ä¼¼ï¼Œç”²åŸºè‹¯ä¸™èƒºä¹Ÿä¼šå¯¼è‡´å¯¹[è¡€æ¸…ç´ ](/wiki/Serotonin) [ç¥ç»å…ƒ](/wiki/Neurons)çš„ç¥ç»æ¯’æ€§ã€‚[\[33\]](#cite_note-Krasnova2009-33) å·²ç»è¯æ˜ï¼Œé«˜æ ¸å¿ƒä½“æ¸©ä¸ç”²åŸºè‹¯ä¸™èƒºç¥ç»æ¯’æ€§ä½œç”¨çš„å¢åŠ ç›¸å…³ã€‚[\[34\]](#cite_note-34) ç”±äºç”²åŸºè‹¯ä¸™èƒºå¯¹å¤šå·´èƒºç¥ç»å…ƒè¯±å¯¼çš„ç¥ç»æ¯’æ€§ï¼Œé•¿æœŸä½¿ç”¨ä¹Ÿå¯èƒ½å¯¼è‡´æŒç»­æ•°æœˆç”šè‡³é•¿è¾¾ä¸€å¹´çš„æ€¥æ€§æˆ’æ–­åç—‡çŠ¶ã€‚[\[29\]](#cite_note-Cruickshank2009-29)

### ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›

ä¸å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)ä¸€æ ·ï¼Œé•¿æœŸä½¿ç”¨ç”²åŸºè‹¯ä¸™èƒºå¯è¢«è§†ä¸ºææ˜“ä¸Šç˜¾ï¼Œå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œå¹¶ä¸”èƒ½å¤Ÿå¯¼è‡´æŸäº›ä½¿ç”¨è€…äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚å½“æˆç˜¾å½¢æˆåï¼Œå¦‚æœä¸€ä¸ªäººçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ[æˆ’æ–­ååº”](/wiki/Withdrawal_effects)ã€‚

é•¿æœŸå’Œé‡å¤ä½¿ç”¨ä¼šè¿…é€Ÿå¯¹ç”²åŸºè‹¯ä¸™èƒºçš„æ•ˆåº”äº§ç”Ÿè€å—æ€§ã€‚[\[35\]](#cite_note-35)[\[36\]](#cite_note-36) è¿™å¯¼è‡´ä½¿ç”¨è€…å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚ä¹‹åï¼Œè€å—æ€§éœ€è¦å¤§çº¦ 3 - 7 å¤©æ‰èƒ½å‡å°‘åˆ°ä¸€åŠï¼Œ1 - 2 å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿æ°´å¹³ï¼ˆåœ¨ä¸ç»§ç»­æ‘„å…¥çš„æƒ…å†µä¸‹ï¼‰ã€‚ç”²åŸºè‹¯ä¸™èƒºä¸æ‰€æœ‰[å¤šå·´èƒºèƒ½](/wiki/Dopamine) [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æœç”¨ç”²åŸºè‹¯ä¸™èƒºåï¼Œæ‰€æœ‰[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)çš„æ•ˆæœéƒ½ä¼šé™ä½ã€‚

å…³äºæ²»ç–—[è‹¯ä¸™èƒº](/wiki/Amphetamine)å’Œç”²åŸºè‹¯ä¸™èƒºä¾èµ–å’Œæ»¥ç”¨çš„æœ‰æ•ˆæ–¹æ³•çš„è¯æ®æœ‰é™ã€‚[\[37\]](#cite_note-37) é‰´äºæ­¤ï¼Œ[æ°Ÿè¥¿æ±€](/wiki/Fluoxetine)å’Œ[ä¸™å’ªå—ª](/wiki/Imipramine)åœ¨æ²»ç–—æ»¥ç”¨å’Œæˆç˜¾æ–¹é¢ä¼¼ä¹æœ‰ä¸€äº›æœ‰é™çš„ç›Šå¤„ï¼Œâ€œæ²¡æœ‰ä»»ä½•æ²»ç–—æ–¹æ³•è¢«è¯æ˜å¯¹æ²»ç–—ç”²åŸºè‹¯ä¸™èƒºä¾èµ–å’Œæ»¥ç”¨æœ‰æ•ˆâ€ã€‚

åœ¨é«˜åº¦ä¾èµ–çš„[è‹¯ä¸™èƒº](/wiki/Amphetamine)å’Œç”²åŸºè‹¯ä¸™èƒºæ»¥ç”¨è€…ä¸­ï¼Œâ€œå½“é•¿æœŸå¤§é‡ä½¿ç”¨è€…çªç„¶åœæ­¢ä½¿ç”¨ç”²åŸºè‹¯ä¸™èƒºæ—¶ï¼Œè®¸å¤šäººæŠ¥å‘Šåœ¨æœ€åä¸€æ¬¡æœè¯å 24 å°æ—¶å†…ä¼šå‡ºç°æœ‰æ—¶é™çš„æˆ’æ–­ç»¼åˆå¾â€ã€‚[\[38\]](#cite_note-Shoptaw2009-38) é•¿æœŸã€é«˜å‰‚é‡ä½¿ç”¨è€…çš„æˆ’æ–­ç—‡çŠ¶é¢‘ç¹å‘ç”Ÿï¼Œé«˜è¾¾ 87.6% çš„ç—…ä¾‹ä¼šå‡ºç°ï¼Œå¹¶ä¸”æŒç»­ä¸‰åˆ°å››å‘¨ï¼Œåœ¨ç¬¬ä¸€å‘¨ä¼šå‡ºç°æ˜æ˜¾çš„â€œå´©æºƒâ€æœŸã€‚[\[38\]](#cite_note-Shoptaw2009-38) ç”²åŸºè‹¯ä¸™èƒºæˆ’æ–­ç—‡çŠ¶å¯èƒ½åŒ…æ‹¬ç„¦è™‘ã€è¯ç‰©æ¸´æœ›ã€çƒ¦èºæƒ…ç»ªã€ç–²åŠ³ã€é£Ÿæ¬²å¢åŠ ã€è¿åŠ¨å¢åŠ æˆ–å‡å°‘ã€ç¼ºä¹åŠ¨åŠ›ã€å¤±çœ æˆ–å—œç¡ï¼Œä»¥åŠç”ŸåŠ¨æˆ–æ¸…é†’çš„æ¢¦ã€‚[\[38\]](#cite_note-Shoptaw2009-38) æˆ’æ–­ç—‡çŠ¶ä¸ä¾èµ–ç¨‹åº¦ï¼ˆå³æ»¥ç”¨ç¨‹åº¦ï¼‰ç›¸å…³ã€‚[\[38\]](#cite_note-Shoptaw2009-38) ä¸ç”²åŸºè‹¯ä¸™èƒºæˆ’æ–­ç›¸å…³çš„ç²¾ç¥æŠ‘éƒæ¯”[å¯å¡å› ](/wiki/Cocaine)æˆ’æ–­æŒç»­æ—¶é—´æ›´é•¿ä¸”æ›´ä¸¥é‡ã€‚[\[39\]](#cite_note-39)

è™½ç„¶å¾ˆæ˜æ˜¾æ°”åŒ–ç”²åŸºè‹¯ä¸™èƒºæ¯”å£æœæˆ–é¼»å¸è‹¯ä¸™èƒºæ›´å®¹æ˜“ä¸Šç˜¾ï¼Œä½†å…³äºè¯ç‰©æœ¬èº«æ˜¯å¦æœ¬è´¨ä¸Šæ›´å®¹æ˜“ä¸Šç˜¾ï¼Œå¦‚æœæ˜¯ï¼Œè¿™ç§å·®å¼‚æœ‰å¤šé‡è¦ï¼Œè¿˜å­˜åœ¨äº‰è®®ã€‚é™¤äº†ä½œç”¨æŒç»­æ—¶é—´å¤–ï¼Œè¿™ä¸¤ç§è¯ç‰©çš„ä¸»è¦åŒºåˆ«åœ¨äºç”²åŸºè‹¯ä¸™èƒºçš„ä¸­æ¢æ´»æ€§æ¯”ä¾‹æ›´é«˜ï¼Œå¤–å‘¨æ´»æ€§æ¯”ä¾‹æ›´ä½ã€‚åŸå› ä¹‹ä¸€æ˜¯ç”²åŸºåŸºå›¢å¢åŠ çš„è„‚æº¶æ€§å¯¼è‡´æ›´å¿«çš„ä¸­æ¢å¸æ”¶ã€‚å¦ä¸€ä¸ªåŸå› æ˜¯ç”²åŸºè‹¯ä¸™èƒºåœ¨ç­‰æ•ˆå‰‚é‡ä¸‹é‡Šæ”¾çš„å¤šå·´èƒºæ¯”ä¾‹æ›´é«˜ã€‚D-ç”²åŸºè‹¯ä¸™èƒºä»çªè§¦é‡Šæ”¾çš„å¤šå·´èƒºä¸å»ç”²è‚¾ä¸Šè…ºç´ çš„æ¯”ç‡çº¦ä¸º 1:1.3ï¼Œè€Œ d-è‹¯ä¸™èƒºçº¦ä¸º 1:2ã€‚[\[40\]](#cite_note-40) å®ƒä»¬å¯¹å»ç”²è‚¾ä¸Šè…ºç´  (NET) å’Œå¤šå·´èƒº (DAT) è½¬è¿ä½“çš„å½±å“æ›´ç›¸ä¼¼ï¼Œä½†ç•¥æœ‰ä¸åŒã€‚D-ç”²åŸºè‹¯ä¸™èƒºå€¾å‘äº NETï¼Œå…¶ç³»æ•°çº¦ä¸º 4ï¼Œè€Œ d-è‹¯ä¸™èƒºçº¦ä¸º 5ã€‚D-ç”²åŸºè‹¯ä¸™èƒºä¹Ÿç¨å¾®æ›´å…·è¡€æ¸…ç´ èƒ½ã€‚è¿™ç§å·®å¼‚å¯èƒ½å¾®ä¸è¶³é“ï¼Œå› ä¸º d-ç”²åŸºè‹¯ä¸™èƒºçš„è¡€æ¸…ç´ ä¸å»ç”²è‚¾ä¸Šè…ºç´ é‡Šæ”¾æ¯”ç‡ä»…ä¸º 1:60ï¼Œè€Œ d-è‹¯ä¸™èƒºä¸º 1:80ã€‚è¿™ä¸¤ç§è¯ç‰©å¯¹è¡€æ¸…ç´ è½¬è¿ä½“ (SERT) éƒ½æ²¡æœ‰æ˜æ˜¾çš„äº²å’ŒåŠ›ã€‚

è¿™ç§ç”²åŸºè‹¯ä¸™èƒºä¸­æ¢ä¸å¤–å‘¨æ•ˆåº”çš„å¢åŠ ä¸å…´å¥‹å‰‚ä½¿ç”¨è€…çš„æ™®éä¸»è§‚æ„Ÿå—ä¸€è‡´ï¼Œå³ç”²åŸºè‹¯ä¸™èƒºå¸¦æ¥çš„å¿«æ„Ÿæœ¬è´¨ä¸Šè¾ƒå°‘æœ‰â€œç´§å¼ ä¸å®‰â€çš„ç‰¹è´¨ã€‚ä¸åˆ©çš„ä¸€é¢æ˜¯ï¼Œè¿™ç§åŒæ¶æ•ˆåº”å¯èƒ½æ˜¯æœ‰ç›Šçš„ï¼Œå› ä¸ºå®ƒä¼šé˜»æ­¢æœ‰å®³ç¨‹åº¦çš„ä½¿ç”¨ã€‚ç›®å‰å°šä¸æ¸…æ¥šè¿™ç§å·®å¼‚ä¼šäº§ç”Ÿä»€ä¹ˆç°å®å½±å“ã€‚ä¸€é¡¹é’ˆå¯¹ 13 åç”²åŸºè‹¯ä¸™èƒºä½¿ç”¨è€…çš„åŒç›²ä½†å°å‹ç ”ç©¶æ˜¾ç¤ºï¼Œä½¿ç”¨è€…ä»…å¯¹ç”²åŸºè‹¯ä¸™èƒºè¡¨ç°å‡ºè½»å¾®çš„åå¥½ï¼Œè¿™å¯èƒ½è§£é‡Šä¸ºä½¿ç”¨è€…å¯¹è¯¥è¯ç‰©æ›´ç†Ÿæ‚‰ã€‚[\[41\]](#cite_note-41)

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¯¥ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/home.md)ã€‚

### ç²¾ç¥ç—…

ä¸»æ¡ç›®ï¼š[å…´å¥‹å‰‚ç²¾ç¥ç—…](/wiki/Stimulant_psychosis)

æ»¥ç”¨ç”²åŸºè‹¯ä¸™èƒºå¯èƒ½å¯¼è‡´å…´å¥‹å‰‚ç²¾ç¥ç—…ï¼Œå¯èƒ½è¡¨ç°å‡ºå¤šç§ç—‡çŠ¶ï¼ˆä¾‹å¦‚ï¼Œ[åæ‰§](/wiki/Paranoia)ã€[å¹»è§‰](/wiki/External_hallucinations)ã€[å¦„æƒ³](/wiki/Delusions)ï¼‰ã€‚[\[38\]](#cite_note-Shoptaw2009-38) ä¸€ç¯‡å…³äºæ²»ç–—[è‹¯ä¸™èƒº](/wiki/Amphetamine)ã€[å³æ—‹è‹¯ä¸™èƒº](/wiki/Dextroamphetamine)å’Œç”²åŸºè‹¯ä¸™èƒºæ»¥ç”¨å¼•èµ·çš„ç²¾ç¥ç—…çš„ç»¼è¿°æŒ‡å‡ºï¼Œå¤§çº¦ 5â€“15% çš„ä½¿ç”¨è€…æœªèƒ½å®Œå…¨åº·å¤ã€‚[\[38\]](#cite_note-Shoptaw2009-38)[\[42\]](#cite_note-42) åŒä¸€ç¯‡ç»¼è¿°æ–­è¨€ï¼ŒåŸºäºè‡³å°‘ä¸€é¡¹è¯•éªŒï¼Œ[æŠ—ç²¾ç¥ç—…](/wiki/Antipsychotic)è¯ç‰©å¯æœ‰æ•ˆè§£å†³æ€¥æ€§è‹¯ä¸™èƒºç²¾ç¥ç—…çš„ç—‡çŠ¶ã€‚[\[38\]](#cite_note-Shoptaw2009-38) æ²»ç–—æ€§ä½¿ç”¨æå°‘å¼•èµ·ç²¾ç¥ç—…ã€‚[\[43\]](#cite_note-43)

### è¿‡é‡

ç”²åŸºè‹¯ä¸™èƒºè¿‡é‡å¯èƒ½å¯¼è‡´å„ç§ç—‡çŠ¶ï¼Œåœ¨å¤§é‡ä½¿ç”¨æ—¶å¯èƒ½è‡´å‘½ã€‚[\[44\]](#cite_note-44) ä¸­åº¦è¿‡é‡çš„ç”²åŸºè‹¯ä¸™èƒºå¯èƒ½è¯±å‘å¿ƒå¾‹å¤±å¸¸ã€æ„è¯†æ¨¡ç³Šã€æ’å°¿å›°éš¾ã€é«˜è¡€å‹æˆ–ä½è¡€å‹ã€ä½“æ¸©è¿‡é«˜ã€åå°„äº¢è¿›ã€è‚Œç—›ã€ä¸¥é‡æ¿€è¶Šã€å‘¼å¸æ€¥ä¿ƒã€éœ‡é¢¤ã€æ’å°¿çŠ¹è±«å’Œå°¿æ½´ç•™ç­‰ç—‡çŠ¶ã€‚[\[45\]](#cite_note-45) æå¤§å‰‚é‡çš„è¿‡é‡å¯èƒ½äº§ç”Ÿè‚¾ä¸Šè…ºç´ èƒ½é£æš´ã€ç”²åŸºè‹¯ä¸™èƒºç²¾ç¥ç—…ã€æ— å°¿ã€å¿ƒæºæ€§ä¼‘å…‹ã€è„‘å‡ºè¡€ã€å¾ªç¯è¡°ç«­ã€é«˜çƒ­ã€è‚ºåŠ¨è„‰é«˜å‹ã€è‚¾è¡°ç«­ã€æ¨ªçº¹è‚Œæº¶è§£ã€[è¡€æ¸…ç´ ç»¼åˆå¾](/wiki/Serotonin_syndrome)å’ŒæŸç§å½¢å¼çš„åˆ»æ¿è¡Œä¸ºï¼ˆâ€œtweakingâ€ï¼‰ã€‚ç”²åŸºè‹¯ä¸™èƒºè¿‡é‡ä¹Ÿå¯èƒ½ç”±äºå¤šå·´èƒºèƒ½å’Œè¡€æ¸…ç´ èƒ½ç¥ç»æ¯’æ€§è€Œå¯¼è‡´è½»å¾®çš„è„‘æŸä¼¤ã€‚[\[28\]](#cite_note-Nestler2009-28)[\[33\]](#cite_note-Krasnova2009-33) è‡´å‘½çš„ç”²åŸºè‹¯ä¸™èƒºä¸­æ¯’æ­»äº¡ä¹‹å‰é€šå¸¸ä¼šå‡ºç°æŠ½æå’Œæ˜è¿·ã€‚[\[46\]](#cite_note-46)

#### ç´§æ€¥æ²»ç–—

æ€¥æ€§ç”²åŸºè‹¯ä¸™èƒºè¿‡é‡çš„æ²»ç–—ä¸»è¦æ˜¯å¯¹ç—‡æ²»ç–—ï¼Œç»™äºˆ[è‹¯äºŒæ°®å“ç±»è¯ç‰©](/wiki/Benzodiazepine)å¯ç¼“è§£æ¿€è¶Šã€é«˜è¡€å‹ã€å¿ƒåŠ¨è¿‡é€Ÿå’Œç™«ç—«å‘ä½œç­‰ç—‡çŠ¶ã€‚[\[47\]](#cite_note-47)

### ä¼¤å®³å‡å°‘

ç ”ç©¶è¡¨æ˜ï¼Œ[N-ä¹™é…°åŠèƒ±æ°¨é…¸](/wiki/N-acetylcysteine) (NAC) å¯ä»¥é˜»æ–­ç”²åŸºè‹¯ä¸™èƒºçš„æœ‰å®³ç¥ç»æ¯’æ€§ä½œç”¨ï¼ŒåŒæ—¶é˜²æ­¢å¤§é¼ ä½“å†…çš„ç¥ç»é€’è´¨è€—ç«­[\[48\]](#cite_note-48)ï¼Œç›®å‰æ­£åœ¨è¿›è¡Œæ²»ç–—äººç±»ç”²åŸºè‹¯ä¸™èƒºä¾èµ–çš„ä¸´åºŠè¯•éªŒã€‚NAC ä¹Ÿå¯èƒ½æœ‰æ•ˆå‡å°‘æ¸´æœ›å’Œå¿ƒç†ä¾èµ–ã€‚[\[49\]](#cite_note-49) NAC åŠè¡°æœŸçŸ­ï¼Œç¼“é‡Šåˆ¶å‰‚å¯èƒ½æ›´é€‚åˆç”¨äºå‡å°‘ä¼¤å®³ã€‚ç¡’ä¹Ÿè¢«è¯æ˜å¯ä»¥ä¿æŠ¤å¤§è„‘å…å—å†°æ¯’è¯±å¯¼çš„ç¥ç»æ¯’æ€§ã€‚[\[50\]](#cite_note-50) ç„¶è€Œï¼Œå€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•°æ®æ˜¯åˆæ­¥çš„ï¼Œå¯èƒ½ä¸é€‚ç”¨äºäººç±»ã€‚

### å±é™©çš„è¯ç‰©è”ç”¨

***è­¦å‘Šï¼š**è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚ä»¥ä¸‹åˆ—å‡ºçš„éƒ¨åˆ†ç›¸äº’ä½œç”¨æ¥æºäº [TripSit](https://combo.tripsit.me)ã€‚*

*   **é…’ç²¾ (Alcohol)** - åœ¨ä½¿ç”¨å…´å¥‹å‰‚æ—¶é¥®é…’è¢«è®¤ä¸ºæ˜¯æœ‰é£é™©çš„ï¼Œå› ä¸ºå®ƒä¼šé™ä½èº«ä½“ç”¨æ¥è¡¡é‡é†‰é…’ç¨‹åº¦çš„é•‡é™ä½œç”¨ã€‚è¿™é€šå¸¸ä¼šå¯¼è‡´è¿‡åº¦é¥®é…’ï¼ŒæŠ‘åˆ¶åŠ›å¤§å¤§é™ä½ï¼Œå¢åŠ è‚è„æŸä¼¤å’Œè„±æ°´çš„é£é™©ã€‚å…´å¥‹å‰‚çš„ä½œç”¨è¿˜ä¼šè®©äººå–åˆ°è¶…è¿‡å¹³æ—¶å¯èƒ½æ˜å€’çš„ç¨‹åº¦ï¼Œä»è€Œå¢åŠ é£é™©ã€‚å¦‚æœä½ å†³å®šè¿™æ ·åšï¼Œä½ åº”è¯¥è®¾å®šæ¯å°æ—¶é¥®é…’é‡çš„é™åˆ¶å¹¶ä¸¥æ ¼éµå®ˆï¼Œå¹¶è®°ä½ä½ ä¼šæ„Ÿè§‰ä¸åˆ°é…’ç²¾å’Œå…´å¥‹å‰‚çš„ä½œç”¨ã€‚
*   **GHB**/**GBL** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é•‡é™å‰‚ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼ŒGHB/GBL çš„æŠ‘åˆ¶ä½œç”¨å¯èƒ½ä¼šå‹å€’ä½¿ç”¨è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚
*   **[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) (Opioids)** - å…´å¥‹å‰‚ä¼šå¢åŠ å‘¼å¸é¢‘ç‡ï¼Œå…è®¸æ‘„å…¥æ›´é«˜å‰‚é‡çš„é˜¿ç‰‡ç±»è¯ç‰©ã€‚å¦‚æœå…´å¥‹å‰‚å…ˆå¤±æ•ˆï¼Œé˜¿ç‰‡ç±»è¯ç‰©å¯èƒ½ä¼šå‹å€’æ‚£è€…å¹¶å¯¼è‡´å‘¼å¸åœæ­¢ã€‚
*   **å¯å¡å›  (Cocaine)** - å¯å¡å› çš„å¥–èµæ•ˆåº”ç”± DAT æŠ‘åˆ¶å’Œé€šè¿‡ç»†èƒè†œçš„å¤šå·´èƒºèƒåå¢åŠ ä»‹å¯¼ã€‚è‹¯ä¸™èƒºé€šè¿‡ pH ä»‹å¯¼çš„ç½®æ¢æœºåˆ¶é€†è½¬ DAT çš„æ–¹å‘å’Œç»†èƒå†…å›Šæ³¡è½¬è¿çš„æ–¹å‘ï¼Œä»è€Œæ’é™¤äº†é€šè¿‡èƒåé‡Šæ”¾å¤šå·´èƒºçš„å¸¸è§„æœºåˆ¶ï¼Œå› ä¸º Na+/K+ ATP é…¶çš„ä½œç”¨å—åˆ°æŠ‘åˆ¶ã€‚ä½ ä¼šå‘ç°å¯å¡å› å’Œè‹¯ä¸™èƒºç»„åˆä¼šå¯¹å¿ƒè„äº§ç”Ÿå½±å“ï¼Œè¿™æ˜¯ç”±äºéšåæ¿€æ´» 5-HT2B å¼•èµ·çš„ SERT ä»‹å¯¼æœºåˆ¶ï¼Œè¿™æ˜¯è¡€æ¸…ç´ ç›¸å…³ç“£è†œç—…çš„ä¸€ç§æ•ˆåº”ã€‚è‹¯ä¸™èƒºåœ¨æ»¥ç”¨æ¨¡å‹ä¸­é€šå¸¸ä¼šå¯¼è‡´é«˜è¡€å‹ï¼Œè¿™ç§ç»„åˆå¯èƒ½ä¼šç”±äºç“£è†œæ“ä½œæœŸé—´çš„æ¹æµè¡€æµè€Œå¢åŠ æ™•å¥çš„æœºä¼šã€‚å¯å¡å› çš„å¥–èµæœºåˆ¶ä¼šè¢«è‹¯ä¸™èƒºçš„ç»™è¯æ‰€é€†è½¬ã€‚[\[51\]](#cite_note-Greenwald2010-51)[\[52\]](#cite_note-Siciliano2018-52)
*   **[å¤§éº»](/è¯ç‰©/å››æ°¢å¤§éº»é…šï¼ˆTHCï¼‰.md) (Cannabis)** - å…´å¥‹å‰‚ä¼šå¢åŠ [ç„¦è™‘](/wiki/Anxiety)æ°´å¹³ä»¥åŠ[æ€ç»´å¾ªç¯](/wiki/Thought_loops)å’Œ[åæ‰§](/wiki/Paranoia)çš„é£é™©ï¼Œè¿™å¯èƒ½å¯¼è‡´è´Ÿé¢ä½“éªŒã€‚
*   **å’–å•¡å›  (Caffeine)** - è¿™ç§å…´å¥‹å‰‚ç»„åˆé€šå¸¸è¢«è®¤ä¸ºæ˜¯ä¸å¿…è¦çš„ï¼Œå¯èƒ½ä¼šå¢åŠ å¿ƒè„è´Ÿæ‹…ï¼Œå¹¶å¯èƒ½å¯¼è‡´ç„¦è™‘å’Œèº«ä½“ä¸é€‚ã€‚
*   **Tramadol** - Tramadol å’Œå…´å¥‹å‰‚éƒ½ä¼šå¢åŠ ç™«ç—«å‘ä½œçš„é£é™©ã€‚
*   **[å³ç¾æ²™èŠ¬](/è¯ç‰©/å³ç¾æ²™èŠ¬.md) (DXM)** - ä¸¤ç§ç‰©è´¨éƒ½ä¼šæé«˜å¿ƒç‡ï¼Œåœ¨æç«¯æƒ…å†µä¸‹ï¼Œç”±è¿™äº›ç‰©è´¨å¼•èµ·çš„æƒŠæå‘ä½œå·²å¯¼è‡´æ›´ä¸¥é‡çš„å¿ƒè„é—®é¢˜ã€‚
*   **[æ°¯èƒºé…®](/è¯ç‰©/æ°¯èƒºé…®.md) (Ketamine)** - è‹¯ä¸™èƒºå’Œæ°¯èƒºé…®çš„ç»„åˆå¯èƒ½ä¼šå¯¼è‡´ç±»ä¼¼äºç²¾ç¥åˆ†è£‚ç—‡çš„ç²¾ç¥ç—…ï¼Œä½†ä¸ä¸€å®šæ¯”ä»»ä½•ä¸€ç§ç‰©è´¨å•ç‹¬äº§ç”Ÿçš„ç²¾ç¥ç—…æ›´ä¸¥é‡ï¼Œå°½ç®¡è¿™ä¸€ç‚¹å€¼å¾—å•†æ¦·ã€‚è¿™æ˜¯å› ä¸ºè‹¯ä¸™èƒºèƒ½å¤Ÿå‡è½»æ°¯èƒºé…®å¼•èµ·çš„å·¥ä½œè®°å¿†ç ´åã€‚è‹¯ä¸™èƒºå•ç‹¬ä½¿ç”¨å¯èƒ½å¯¼è‡´å¤¸å¤§å¦„æƒ³ã€åæ‰§æˆ–èº¯ä½“å¦„æƒ³ï¼Œå¯¹é˜´æ€§ç—‡çŠ¶å‡ ä¹æ²¡æœ‰å½±å“ã€‚ç„¶è€Œï¼Œæ°¯èƒºé…®ç”±äºæ”¹å˜äº†æ¦‚å¿µï¼Œä¼šå¯¼è‡´æ€ç»´éšœç¢ã€æ‰§è¡ŒåŠŸèƒ½ç ´åå’Œå¦„æƒ³ã€‚è¿™äº›æœºåˆ¶æ˜¯ç”±äºè‹¯ä¸™èƒºé€šè¿‡å…¶è¯ç†ä½œç”¨å½±å“å¤šå·´èƒºï¼Œå¯¼è‡´ä¸­è„‘è¾¹ç¼˜é€šè·¯ä¸­å¤šå·´èƒºèƒ½æ´»æ€§çš„å¢åŠ ï¼Œä»¥åŠç”±äºæ°¯èƒºé…®çš„ NMDA æ‹®æŠ—ä½œç”¨å¯¼è‡´ä¸­è„‘çš®å±‚é€šè·¯ä¸­å¤šå·´èƒºèƒ½åŠŸèƒ½çš„ç ´åã€‚ä¸¤è€…ç»“åˆï¼Œä½ å¯èƒ½ä¼šé¢„æœŸä¸»è¦æ˜¯æ€ç»´éšœç¢ä»¥åŠé˜³æ€§ç—‡çŠ¶ã€‚[\[53\]](#cite_note-Krystal2005-53)
*   **[PCP](/è¯ç‰©/PCP.md)** - å¢åŠ å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹å’Œèºç‹‚çŠ¶æ€çš„é£é™©ã€‚
*   **Methoxetamine** - å¢åŠ å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹å’Œèºç‹‚çŠ¶æ€çš„é£é™©ã€‚
*   **[è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md)** (ä¾‹å¦‚ ***[LSD](/è¯ç‰©/LSD.md), [éº¦å¸å¡æ—](/wiki/Mescaline), [èµ›æ´›è¥¿å®¾](/wiki/Psilocybin)***) - å¢åŠ [ç„¦è™‘](/wiki/Anxiety)ã€[åæ‰§](/wiki/Paranoia)å’Œ[æ€ç»´å¾ªç¯](/wiki/Thought_loops)çš„é£é™©ã€‚
    +   **25x-NBOMe** - è‹¯ä¸™èƒºå’Œ NBOMes éƒ½æä¾›ç›¸å½“å¤§çš„åˆºæ¿€ï¼Œå½“ç»“åˆä½¿ç”¨æ—¶ï¼Œå®ƒä»¬ä¼šå¯¼è‡´å¿ƒåŠ¨è¿‡é€Ÿã€é«˜è¡€å‹ã€è¡€ç®¡æ”¶ç¼©ï¼Œæç«¯æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚å…´å¥‹å‰‚çš„ç„¦è™‘å’Œèšç„¦æ•ˆåº”ä¹Ÿä¸é€‚åˆä¸è¿·å¹»å‰‚ç»“åˆä½¿ç”¨ï¼Œå› ä¸ºå®ƒä»¬å¯èƒ½å¯¼è‡´ä¸æ„‰å¿«çš„æ€ç»´å¾ªç¯ã€‚å·²çŸ¥ NBOMes ä¼šå¯¼è‡´ç™«ç—«å‘ä½œï¼Œè€Œå…´å¥‹å‰‚ä¼šå¢åŠ è¿™ç§é£é™©ã€‚
    +   **2C-T-x** - æ€€ç–‘å…·æœ‰è½»å¾®çš„ MAOI ç‰¹æ€§ã€‚å¯èƒ½ä¼šå¢åŠ é«˜è¡€å‹å±è±¡çš„é£é™©ã€‚
    +   **5-MeO-xxT** - æ€€ç–‘å…·æœ‰è½»å¾®çš„ MAOI ç‰¹æ€§ã€‚å¯èƒ½ä¼šå¢åŠ é«˜è¡€å‹å±è±¡çš„é£é™©ã€‚
    +   **DOx**
*   **aMT** - aMT å…·æœ‰ MAOI ç‰¹æ€§ï¼Œå¯èƒ½ä¸è‹¯ä¸™èƒºå‘ç”Ÿä¸åˆ©çš„ç›¸äº’ä½œç”¨ã€‚
*   **MAOIs** - MAO-B æŠ‘åˆ¶å‰‚å¯ä»¥ä¸å¯é¢„æµ‹åœ°å¢åŠ è‹¯ä¹™èƒºçš„æ•ˆåŠ›å’ŒæŒç»­æ—¶é—´ã€‚MAO-A æŠ‘åˆ¶å‰‚ä¸è‹¯ä¸™èƒºä¼šå¯¼è‡´é«˜è¡€å‹å±è±¡ã€‚

æ³•å¾‹åœ°ä½
------------

åœ¨è®¸å¤šå¸æ³•ç®¡è¾–åŒºï¼Œç”²åŸºè‹¯ä¸™èƒºçš„ç”Ÿäº§ã€åˆ†é”€ã€é”€å”®å’Œæ‹¥æœ‰å—åˆ°é™åˆ¶æˆ–éæ³•ã€‚[\[54\]](#cite_note-54)[\[55\]](#cite_note-55) ç”²åŸºè‹¯ä¸™èƒºå·²è¢«åˆ—å…¥è”åˆå›½ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹é™„è¡¨ IIã€‚[\[56\]](#cite_note-56)

*   **æ¾³å¤§åˆ©äºš**ï¼šç”²åŸºè‹¯ä¸™èƒºè¢«åˆ—ä¸ºé™„è¡¨ 8ï¼Œè¿™æ„å‘³ç€å®ƒå¯ç”¨äºåŒ»ç–—ç”¨é€”ï¼Œä½†æœªç»æˆæƒæ‹¥æœ‰ã€ç”Ÿäº§æˆ–ä¾›åº”æ˜¯éæ³•çš„ã€‚[\[57\]](#cite_note-57) æˆªè‡³ 2023 å¹´ 10 æœˆ 28 æ—¥ï¼Œåœ¨æ¾³å¤§åˆ©äºšé¦–éƒ½é¢†åœ° (ACT)ï¼ŒæŒæœ‰ 1.5 å…‹ä»¥ä¸‹çš„ä¸ªäººæ•°é‡å·²éåˆ‘äº‹åŒ–ã€‚[\[58\]](#cite_note-58)
*   **å¥¥åœ°åˆ©**ï¼šæ ¹æ® SMG (Suchtmittelgesetz Ã–sterreich)ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”®ç”²åŸºè‹¯ä¸™èƒºæ˜¯éæ³•çš„ã€‚[\[59\]](#cite_note-59)
*   **å·´è¥¿**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯ F2 ç±»è¿ç¦ç²¾ç¥æ´»æ€§ç‰©è´¨ã€‚[\[60\]](#cite_note-60)
*   **åŠ æ‹¿å¤§**ï¼šç”²åŸºè‹¯ä¸™èƒºåœ¨ CDSA ä¸Šè¢«åˆ—ä¸ºé™„è¡¨ I ç‰©è´¨ã€‚[\[61\]](#cite_note-61)
*   **æ·å…‹å…±å’Œå›½**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯é™„è¡¨ II ç®¡åˆ¶ç‰©è´¨ã€‚[\[62\]](#cite_note-62)
*   **æ³•å›½**ï¼šç”²åŸºè‹¯ä¸™èƒºè¢«åˆ—ä¸ºâ€œstupÃ©fiantâ€ï¼Œå³å…¬è®¤çš„æ»¥ç”¨è¯ç‰©ã€‚æ‹¥æœ‰ã€è´­ä¹°ã€é”€å”®æˆ–åˆ¶é€ å‡å±è¿æ³•ã€‚[\[63\]](#cite_note-63)
*   **å¾·å›½**ï¼šç”²åŸºè‹¯ä¸™èƒºäº 1941 å¹´ 7 æœˆ 1 æ—¥è¢«æ·»åŠ åˆ°é¸¦ç‰‡æ³•ä¸­ã€‚[\[64\]](#cite_note-64) æˆªè‡³ 2008 å¹´ 3 æœˆ 1 æ—¥ï¼Œå®ƒå— Anlage II BtMGï¼ˆ*éº»é†‰å“æ³•ï¼Œé™„è¡¨ II*ï¼‰ç®¡åˆ¶ã€‚[\[65\]](#cite_note-65) åœ¨æ­¤ä¹‹å‰ï¼Œç”±äºå®ƒå±äº Anlage IIIï¼ˆ*é™„è¡¨ III*ï¼‰ï¼Œå› æ­¤å¯ä»¥é€šè¿‡éº»é†‰å“å¤„æ–¹å•å¼€å…·å¤„æ–¹ã€‚[\[66\]](#cite_note-66) æœªç»è®¸å¯åˆ¶é€ ã€æ‹¥æœ‰ã€è¿›å£ã€å‡ºå£ã€è´­ä¹°ã€é”€å”®ã€é‡‡è´­æˆ–åˆ†å‘å‡å±éæ³•ã€‚[\[67\]](#cite_note-67)
*   **æ—¥æœ¬**ï¼šç”²åŸºè‹¯ä¸™èƒºæ ¹æ® 1954 å¹´çš„ã€Šè§‰é†’å‰‚å–ç¼”æ³•ã€‹è¢«ç¦æ­¢ã€‚[\[68\]](#cite_note-68)
*   **è·å…°**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯æ¸…å• I ç®¡åˆ¶ç‰©è´¨ã€‚[\[69\]](#cite_note-69)
*   **æ–°è¥¿å…°**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯ A ç±»ç®¡åˆ¶ç‰©è´¨ã€‚[\[70\]](#cite_note-70)
*   **æ³¢å…°**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯ II-P ç»„ç®¡åˆ¶ç‰©è´¨ã€‚[\[71\]](#cite_note-71)
*   **éŸ©å›½**ï¼šæ ¹æ®è”åˆå›½ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹ï¼ŒéŸ©å›½ç¦æ­¢ä½¿ç”¨ç”²åŸºè‹¯ä¸™èƒºã€‚[\[72\]](#cite_note-72)
*   **ç‘å…¸**ï¼šç”²åŸºè‹¯ä¸™èƒºè¢«è”åˆå›½å½’ç±»ä¸ºè¯ç‰©ï¼Œå¹¶åŒ…å«åœ¨ 1971 å¹´ã€Šç²¾ç¥è¯ç‰©å…¬çº¦ã€‹çš„ P II æ¸…å•ä¸­ï¼Œä»¥åŠç‘å…¸çš„æ¸…å• II ä¸­ã€‚[\[73\]](#cite_note-73)
*   **ç‘å£«**ï¼šç”²åŸºè‹¯ä¸™èƒºæ˜¯ Verzeichnis A ä¸‹ç‰¹åˆ«å‘½åçš„ç®¡åˆ¶ç‰©è´¨ã€‚[\[74\]](#cite_note-74)
*   **è‹±å›½**ï¼šæˆªè‡³ 2007 å¹´ 1 æœˆ 18 æ—¥ï¼Œç”²åŸºè‹¯ä¸™èƒºè¢«åˆ—ä¸º A ç±»è¯ç‰©ã€‚[\[75\]](#cite_note-75)
*   **ç¾å›½**ï¼šåœ¨ç¾å›½ï¼Œç”²åŸºè‹¯ä¸™èƒºæ˜¯é™„è¡¨ II ç®¡åˆ¶ç‰©è´¨ã€‚[\[76\]](#cite_note-76)

å¦è§
--------

*   [è´Ÿè´£ä»»çš„ä½¿ç”¨](/wiki/Responsible_use)
*   [ç²¾ç¥æ´»æ€§ç‰©è´¨ç´¢å¼•](/wiki/Psychoactive_substance_index)
*   [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)
*   [è‹¯ä¹™èƒº](/wiki/Phenethylamine)
*   [å–ä»£è‹¯ä¸™èƒº](/wiki/Substituted_amphetamine)
*   [è‹¯ä¸™èƒº](/wiki/Amphetamine)

å¤–éƒ¨é“¾æ¥
--------------

*   [Methamphetamine (Wikipedia)](http://en.wikipedia.org/wiki/Methamphetamine)
*   [Methamphetamine (Erowid Vault)](http://www.erowid.org/chemicals/meth/meth.shtml)
*   [Methamphetamine (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=2002)
*   [Methamphetamine (DrugBank)](https://go.drugbank.com/drugs/DB01577)
*   [Methamphetamine (Drugs.com)](https://www.drugs.com/methamphetamine.html)
*   [Methamphetamine (Drugs-Forum)](https://drugs-forum.com/wiki/Methamphetamine)

å‚è€ƒæ–‡çŒ®
----------

1. â†‘ [1.0](#cite_ref-Rau2016_1-0) [1.1](#cite_ref-Rau2016_1-1) Rau, T., Ziemniak, J., Poulsen, D. (4 January 2016). ["The neuroprotective potential of low-dose methamphetamine in preclinical models of stroke and traumatic brain injury"](https://www.sciencedirect.com/science/article/pii/S0278584615000469). *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. **64**: 231â€“236. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.pnpbp.2015.02.013](//doi.org/10.1016%2Fj.pnpbp.2015.02.013). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0278-5846](//www.worldcat.org/issn/0278-5846). 
2. [â†‘](#cite_ref-Methamphetamine_.7C_City_Vision_2-0) [*Methamphetamine - City Vision*](https://library.cityvision.edu/methamphetamine) 
3. [â†‘](#cite_ref-erowid_3-0) [*Erowid Methamphetamine (Speed, Crank) Vault*](https://erowid.org/chemicals/meth/meth.shtml) 
4. â†‘ [4.0](#cite_ref-Barr2006_4-0) [4.1](#cite_ref-Barr2006_4-1) Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., Lecomte, T. (September 2006). ["The need for speed: an update on methamphetamine addiction"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557685/). *Journal of Psychiatry and Neuroscience*. **31** (5): 301â€“313. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1180-4882](//www.worldcat.org/issn/1180-4882). 
5. [â†‘](#cite_ref-5) Nagai N (1893) Studies on the components of Ephedraceaein herb medicine. Yakugaku Zasshi 139 :901-933
6. [â†‘](#cite_ref-6) Galbraith, N. (October 2015). ["The methamphetamine problem"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706185/). *BJPsych Bulletin*. **39** (5): 218â€“220. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1192/pb.bp.115.050930](//doi.org/10.1192%2Fpb.bp.115.050930). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [2056-4694](//www.worldcat.org/issn/2056-4694). 
7. [â†‘](#cite_ref-7) Jayanthi, S., Daiwile, A. P., Cadet, J. L. (October 2021). ["Neurotoxicity of methamphetamine: Main effects and mechanisms"](https://linkinghub.elsevier.com/retrieve/pii/S001448862100203X). *Experimental Neurology*. **344**: 113795. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.expneurol.2021.113795](//doi.org/10.1016%2Fj.expneurol.2021.113795). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0014-4886](//www.worldcat.org/issn/0014-4886). 
8. [â†‘](#cite_ref-8) Khoshsirat, S., Khoramgah, M. S., Mahmoudiasl, G.-R., Rezaei-Tavirani, M., Abdollahifar, M.-A., Tahmasebinia, F., Darabi, S., Niknazar, S., Abbaszadeh, H. A. (September 2020). ["LC3 and ATG5 overexpression and neuronal cell death in the prefrontal cortex of postmortem chronic methamphetamine users"](https://linkinghub.elsevier.com/retrieve/pii/S0891061820300715). *Journal of Chemical Neuroanatomy*. **107**: 101802. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.jchemneu.2020.101802](//doi.org/10.1016%2Fj.jchemneu.2020.101802). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0891-0618](//www.worldcat.org/issn/0891-0618). 
9. [â†‘](#cite_ref-9) Edeleano, L. (January 1887). ["Ueber einige Derivate der PhenylmethacrylsÃ¤ure und der PhenylisobuttersÃ¤ure"](https://onlinelibrary.wiley.com/doi/10.1002/cber.188702001142). *Berichte der deutschen chemischen Gesellschaft*. **20** (1): 616â€“622. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/cber.188702001142](//doi.org/10.1002%2Fcber.188702001142). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0365-9496](//www.worldcat.org/issn/0365-9496). 
10. [â†‘](#cite_ref-10) Grobler, S. R., Chikte, U., Westraat, J. (26 June 2011). ["The pH Levels of Different Methamphetamine Drug Samples on the Street Market in Cape Town"](https://www.hindawi.com/journals/isrn/2011/974768/). *ISRN Dentistry*. **2011**: 1â€“4. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.5402/2011/974768](//doi.org/10.5402%2F2011%2F974768). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [2090-4371](//www.worldcat.org/issn/2090-4371). 
11. [â†‘](#cite_ref-11) Rasmussen, N. (21 February 2006). ["Making the First Anti-Depressant: Amphetamine in American Medicine, 1929-1950"](https://academic.oup.com/jhmas/article-lookup/doi/10.1093/jhmas/jrj039). *Journal of the History of Medicine and Allied Sciences*. **61** (3): 288â€“323. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/jhmas/jrj039](//doi.org/10.1093%2Fjhmas%2Fjrj039). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0022-5045](//www.worldcat.org/issn/0022-5045). 
12. [â†‘](#cite_ref-:0_12-0) Rasmussen, N. (September 2011). ["Medical Science and the Military: The Allies' Use of Amphetamine during World War II"](https://direct.mit.edu/jinh/article/42/2/205-233/50354). *The Journal of Interdisciplinary History*. **42** (2): 205â€“233. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1162/JINH_a_00212](//doi.org/10.1162%2FJINH_a_00212). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0022-1953](//www.worldcat.org/issn/0022-1953). 
13. [â†‘](#cite_ref-13) Defalque, R. J., Wright, A. J. (April 2011). ["Methamphetamine for Hitler's Germany: 1937 to 1945"](https://linkinghub.elsevier.com/retrieve/pii/S1522864911500162). *Bulletin of Anesthesia History*. **29** (2): 21â€“32. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S1522-8649(11)50016-2](//doi.org/10.1016%2FS1522-8649%2811%2950016-2). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1522-8649](//www.worldcat.org/issn/1522-8649). 
14. [â†‘](#cite_ref-14) "Historical overview of methamphetamine". Vermont Department of Health. Government of Vermont. Retrieved 29 January 2012.
15. [â†‘](#cite_ref-15) "Controlled Substances Act". United States Food and Drug Administration. 11 June 2009. Retrieved 4 November 2013.
16. [â†‘](#cite_ref-16) Gyenis A. "Forty Years of On the Road 1957â€“1997". wordsareimportant.com. DHARMA beat. Archived from the original on 14 February 2008. Retrieved 18 March 2008.
17. [â†‘](#cite_ref-17) Wilson, A. (2009), [*Mixing the Medicine: The Unintended Consequence of Amphetamine Control on the Northern Soul Scene*](https://papers.ssrn.com/abstract=1339332), Social Science Research Network 
18. [â†‘](#cite_ref-18) Hill, J. (2004), *Paul ErdÅ‘s â€“ Mathematical Genius, Human (In That Order)* 
19. [â†‘](#cite_ref-19) Liddle, D. G., Connor, D. J. (June 2013). ["Nutritional Supplements and Ergogenic Aids"](https://linkinghub.elsevier.com/retrieve/pii/S0095454313000249). *Primary Care: Clinics in Office Practice*. **40** (2): 487â€“505. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.pop.2013.02.009](//doi.org/10.1016%2Fj.pop.2013.02.009). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0095-4543](//www.worldcat.org/issn/0095-4543). 
20. [â†‘](#cite_ref-20) Chawla S, Le Pichon T (2006). "World Drug Report 2006" (PDF). United Nations Office on Drugs and Crime. pp. 128â€“135. Retrieved 2 November 2013.
21. [â†‘](#cite_ref-21) Desoxyn Label (FDA) | <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf>
22. [â†‘](#cite_ref-22) Kish, S. J. (17 June 2008). ["Pharmacologic mechanisms of crystal meth"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413312/). *CMAJ : Canadian Medical Association Journal*. **178** (13): 1679â€“1682. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1503/cmaj.071675](//doi.org/10.1503%2Fcmaj.071675). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0820-3946](//www.worldcat.org/issn/0820-3946). 
23. [â†‘](#cite_ref-23) Haughey, H. M., Brown, J. M., Wilkins, D. G., Hanson, G. R., Fleckenstein, A. E. (28 April 2000). "Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters". *Brain Research*. **863** (1â€“2): 59â€“65. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/s0006-8993(00)02094-1](//doi.org/10.1016%2Fs0006-8993%2800%2902094-1). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0006-8993](//www.worldcat.org/issn/0006-8993). 
24. [â†‘](#cite_ref-24) Lin, M., Sambo, D., Khoshbouei, H. (5 October 2016). "Methamphetamine Regulation of Firing Activity of Dopamine Neurons". *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*. **36** (40): 10376â€“10391. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1523/JNEUROSCI.1392-16.2016](//doi.org/10.1523%2FJNEUROSCI.1392-16.2016). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1529-2401](//www.worldcat.org/issn/1529-2401). 
25. [â†‘](#cite_ref-25) [*How Drugs Affect Neurotransmitters*](https://thebrain.mcgill.ca/flash/i/i_03/i_03_m/i_03_m_par/i_03_m_par_cocaine.html), Canadian Institutes of Health Research, retrieved January 1, 2007 
26. [â†‘](#cite_ref-Nutt_2010_26-0) Nutt DJ, King LA, Phillips LD (November 2010). "Drug harms in the UK: a multicriteria decision analysis". *Lancet*. **376** (9752): 1558â€“1565. [CiteSeerX](http://en.wikipedia.org/wiki/CiteSeerX) [10.1.1.690.1283](//citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.690.1283)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(10)61462-6](//doi.org/10.1016%2FS0140-6736%2810%2961462-6). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier) [21036393](//www.ncbi.nlm.nih.gov/pubmed/21036393). 
27. [â†‘](#cite_ref-27) Nie, L., Zhao, Z., Wen, X., Luo, W., Ju, T., Ren, A., Wu, B., Li, J. (10 April 2020). "Gray-matter structure in long-term abstinent methamphetamine users". *BMC psychiatry*. **20** (1): 158. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1186/s12888-020-02567-3](//doi.org/10.1186%2Fs12888-020-02567-3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1471-244X](//www.worldcat.org/issn/1471-244X). 
28. â†‘ [28.0](#cite_ref-Nestler2009_28-0) [28.1](#cite_ref-Nestler2009_28-1) Nestler, E. J., Hyman, S. E., Malenka, R. C. (2009). *Molecular neuropharmacology: a foundation for clinical neuroscience* (2nd ed ed.). McGraw-Hill Medical. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number) [9780071481274](http://en.wikipedia.org/wiki/Special:BookSources/9780071481274). 
29. â†‘ [29.0](#cite_ref-Cruickshank2009_29-0) [29.1](#cite_ref-Cruickshank2009_29-1) Cruickshank, C. C., Dyer, K. R. (July 2009). "A review of the clinical pharmacology of methamphetamine". *Addiction (Abingdon, England)*. **104** (7): 1085â€“1099. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1360-0443.2009.02564.x](//doi.org/10.1111%2Fj.1360-0443.2009.02564.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1360-0443](//www.worldcat.org/issn/1360-0443). 
30. [â†‘](#cite_ref-30) Thrash, B., Thiruchelvan, K., Ahuja, M., Suppiramaniam, V., Dhanasekaran, M. (November 2009). ["Methamphetamine-induced neurotoxicity: the road to Parkinson's disease"](https://linkinghub.elsevier.com/retrieve/pii/S1734114009701586). *Pharmacological Reports*. **61** (6): 966â€“977. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S1734-1140(09)70158-6](//doi.org/10.1016%2FS1734-1140%2809%2970158-6). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1734-1140](//www.worldcat.org/issn/1734-1140). 
31. [â†‘](#cite_ref-31) Sulzer, D., Zecca, L. (February 2000). "Intraneuronal dopamine-quinone synthesis: a review". *Neurotoxicity Research*. **1** (3): 181â€“195. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF03033289](//doi.org/10.1007%2FBF03033289). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1029-8428](//www.worldcat.org/issn/1029-8428). 
32. [â†‘](#cite_ref-32) Miyazaki, I., Asanuma, M. (June 2008). "Dopaminergic neuron-specific oxidative stress caused by dopamine itself". *Acta Medica Okayama*. **62** (3): 141â€“150. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.18926/AMO/30942](//doi.org/10.18926%2FAMO%2F30942). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0386-300X](//www.worldcat.org/issn/0386-300X). 
33. â†‘ [33.0](#cite_ref-Krasnova2009_33-0) [33.1](#cite_ref-Krasnova2009_33-1) Krasnova, I. N., Cadet, J. L. (May 2009). "Methamphetamine toxicity and messengers of death". *Brain Research Reviews*. **60** (2): 379â€“407. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.brainresrev.2009.03.002](//doi.org/10.1016%2Fj.brainresrev.2009.03.002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0165-0173](//www.worldcat.org/issn/0165-0173). 
34. [â†‘](#cite_ref-34) Yuan, J., Hatzidimitriou, G., Suthar, P., Mueller, M., McCann, U., Ricaurte, G. (March 2006). "Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys". *The Journal of Pharmacology and Experimental Therapeutics*. **316** (3): 1210â€“1218. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1124/jpet.105.096503](//doi.org/10.1124%2Fjpet.105.096503). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0022-3565](//www.worldcat.org/issn/0022-3565). 
35. [â†‘](#cite_ref-35) PÃ©rez-MaÃ±Ã¡, C., Castells, X., Torrens, M., CapellÃ , D., Farre, M. (2 September 2013). "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". *The Cochrane Database of Systematic Reviews* (9): CD009695. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/14651858.CD009695.pub2](//doi.org/10.1002%2F14651858.CD009695.pub2). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1469-493X](//www.worldcat.org/issn/1469-493X). 
36. [â†‘](#cite_ref-36) <http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html>
37. [â†‘](#cite_ref-37) Srisurapanont, M., Jarusuraisin, N., Kittirattanapaiboon, P. (2001). "Treatment for amphetamine dependence and abuse". *The Cochrane Database of Systematic Reviews* (4): CD003022. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/14651858.CD003022](//doi.org/10.1002%2F14651858.CD003022). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1469-493X](//www.worldcat.org/issn/1469-493X). 
38. â†‘ [38.0](#cite_ref-Shoptaw2009_38-0) [38.1](#cite_ref-Shoptaw2009_38-1) [38.2](#cite_ref-Shoptaw2009_38-2) [38.3](#cite_ref-Shoptaw2009_38-3) [38.4](#cite_ref-Shoptaw2009_38-4) [38.5](#cite_ref-Shoptaw2009_38-5) [38.6](#cite_ref-Shoptaw2009_38-6) Shoptaw, S. J., Kao, U., Heinzerling, K., Ling, W. (15 April 2009). "Treatment for amphetamine withdrawal". *The Cochrane Database of Systematic Reviews* (2): CD003021. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/14651858.CD003021.pub2](//doi.org/10.1002%2F14651858.CD003021.pub2). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1469-493X](//www.worldcat.org/issn/1469-493X). 
39. [â†‘](#cite_ref-39) Winslow, B. T., Voorhees, K. I., Pehl, K. A. (15 October 2007). "Methamphetamine abuse". *American Family Physician*. **76** (8): 1169â€“1174. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0002-838X](//www.worldcat.org/issn/0002-838X). 
40. [â†‘](#cite_ref-40) <https://en.wikipedia.org/wiki/Monoamine_releasing_agent#Activity_profiles>
41. [â†‘](#cite_ref-41) Kirkpatrick, M. G., Gunderson, E. W., Johanson, C.-E., Levin, F. R., Foltin, R. W., Hart, C. L. (April 2012). ["Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475187/). *Addiction (Abingdon, England)*. **107** (4): 783â€“791. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1360-0443.2011.03706.x](//doi.org/10.1111%2Fj.1360-0443.2011.03706.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0965-2140](//www.worldcat.org/issn/0965-2140). 
42. [â†‘](#cite_ref-42) Hofmann, F. G. (1983). *A handbook on drug and alcohol abuse: the biomedical aspects* (2nd ed ed.). Oxford University Press. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number) [9780195030563](http://en.wikipedia.org/wiki/Special:BookSources/9780195030563). 
43. [â†‘](#cite_ref-43) <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf>
44. [â†‘](#cite_ref-44) "Desoxyn Prescribing Information" | <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf>
45. [â†‘](#cite_ref-45) Goodman, L. S., Brunton, L. L., Chabner, B., Knollmann, B. C., eds. (2011). *Goodman & Gilmanâ€™s pharmacological basis of therapeutics* (12th ed ed.). McGraw-Hill. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number) [9780071624428](http://en.wikipedia.org/wiki/Special:BookSources/9780071624428). 
46. [â†‘](#cite_ref-46) "Desoxyn Prescribing Information" | <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf>
47. [â†‘](#cite_ref-47) Robin, S., Michael, B. (2010). ["The clinical toxicology of metamfetamine"](https://www.tandfonline.com/doi/full/10.3109/15563650.2010.516752). *Clinical Toxicology*. **48** (7): 676. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.3109/15563650.2010.516752](//doi.org/10.3109%2F15563650.2010.516752). 
48. [â†‘](#cite_ref-48) Fukami, G., Hashimoto, K., Koike, K., Okamura, N., Shimizu, E., Iyo, M. (July 2004). ["Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine"](https://linkinghub.elsevier.com/retrieve/pii/S0006899304007164). *Brain Research*. **1016** (1): 90â€“95. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.brainres.2004.04.072](//doi.org/10.1016%2Fj.brainres.2004.04.072). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0006-8993](//www.worldcat.org/issn/0006-8993). 
49. [â†‘](#cite_ref-49) Mousavi, S. G., Sharbafchi, M. R., Salehi, M., Peykanpour, M., Karimian Sichani, N., Maracy, M. (January 2015). "The efficacy of N-acetylcysteine in the treatment of methamphetamine dependence: a double-blind controlled, crossover study". *Archives of Iranian Medicine*. **18** (1): 28â€“33. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.brainres.2004.04.072](//doi.org/10.1016%2Fj.brainres.2004.04.072). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1735-3947](//www.worldcat.org/issn/1735-3947). 
50. [â†‘](#cite_ref-50) Imam, S. Z., Newport, G. D., Islam, F., Slikker, W., Ali, S. F. (13 February 1999). ["Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity"](https://www.sciencedirect.com/science/article/pii/S0006899398013110). *Brain Research*. **818** (2): 575â€“578. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0006-8993(98)01311-0](//doi.org/10.1016%2FS0006-8993%2898%2901311-0). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0006-8993](//www.worldcat.org/issn/0006-8993). 
51. [â†‘](#cite_ref-Greenwald2010_51-0) Greenwald, M. K., Lundahl, L. H., Steinmiller, C. L. (December 2010). ["Sustained Release d-Amphetamine Reduces Cocaine but not 'Speedball'-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers"](http://www.nature.com/articles/npp2010175). *Neuropsychopharmacology*. **35** (13): 2624â€“2637. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1038/npp.2010.175](//doi.org/10.1038%2Fnpp.2010.175). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0893-133X](//www.worldcat.org/issn/0893-133X). 
52. [â†‘](#cite_ref-Siciliano2018_52-0) Siciliano, C. A., Saha, K., Calipari, E. S., Fordahl, S. C., Chen, R., Khoshbouei, H., Jones, S. R. (10 January 2018). ["Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation"](https://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2604-17.2017). *The Journal of Neuroscience*. **38** (2): 484â€“497. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1523/JNEUROSCI.2604-17.2017](//doi.org/10.1523%2FJNEUROSCI.2604-17.2017). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0270-6474](//www.worldcat.org/issn/0270-6474). 
53. [â†‘](#cite_ref-Krystal2005_53-0) Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., Dâ€™Souza, D. C. (1 September 2005). ["Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function"](http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archpsyc.62.9.985). *Archives of General Psychiatry*. **62** (9): 985. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1001/archpsyc.62.9.985](//doi.org/10.1001%2Farchpsyc.62.9.985). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0003-990X](//www.worldcat.org/issn/0003-990X). 
54. [â†‘](#cite_ref-54) <http://www.unodc.org/pdf/youthnet/ATS.pdf>
55. [â†‘](#cite_ref-55) <http://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf>
56. [â†‘](#cite_ref-56) <http://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf>
57. [â†‘](#cite_ref-57) Health, [*Poisons Standard February 2019*](https://www.legislation.gov.au/Details/F2019L00032/Html/Text#_Toc532805057) 
58. [â†‘](#cite_ref-58) <https://www.health.act.gov.au/about-our-health-system/population-health/drug-law-reform>
59. [â†‘](#cite_ref-59) ["Suchtgiftverordnung"](https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053). Government of Austria. Retrieved February 18, 2022. 
60. [â†‘](#cite_ref-60) <https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451>
61. [â†‘](#cite_ref-61) ["Controlled Drugs and Substances Act - SCHEDULE I"](https://www.laws-lois.justice.gc.ca/eng/acts/C-38.8/page-13.html#docCont). Government of Canada. Retrieved December 19, 2019. 
62. [â†‘](#cite_ref-62) <https://www.zakonyprolidi.cz/cs/2013-463>
63. [â†‘](#cite_ref-63) [*ArrÃªtÃ© du 22 fÃ©vrier 1990 fixant la liste des substances classÃ©es comme stupÃ©fiants*](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/) 
64. [â†‘](#cite_ref-64) ["The Nazi Death Machine: Hitler's Drugged Soldiers"](https://www.spiegel.de/international/the-nazi-death-machine-hitler-s-drugged-soldiers-a-354606.html). Spiegel Online. May 6, 2005. Retrieved December 23, 2019. 
65. [â†‘](#cite_ref-65) ["Anlage II BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 23, 2019. 
66. [â†‘](#cite_ref-66) ["Einundzwanzigste Verordnung zur Ã„nderung betÃ¤ubungsmittelrechtlicher Vorschriften"](https://www.bgbl.de/xaver/bgbl/start.xav?start=//*%5B@attr_id=%27bgbl108s0246.pdf%27%5D) (in German). Bundesanzeiger Verlag. Retrieved December 23, 2019. 
67. [â†‘](#cite_ref-67) ["Â§ 29 BtMG"](https://www.gesetze-im-internet.de/btmg_1981/__29.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 23, 2019. 
68. [â†‘](#cite_ref-68) [*UNODC - Bulletin on Narcotics - 1957 Issue 3 - 002*](//www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1957-01-01_3_page003.html) 
69. [â†‘](#cite_ref-69) ["Opiumwet"](https://wetten.overheid.nl/BWBR0001941/2009-07-01) (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties. Retrieved December 19, 2019. 
70. [â†‘](#cite_ref-70) ["Schedule 1 - Class A controlled drugs"](https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html). Parliamentary Counsel Office. 
71. [â†‘](#cite_ref-71) [*Ustawa z dnia 24 kwietnia 2015 r. o zmianie ustawy o przeciwdziaÅ‚aniu narkomanii oraz niektÃ³rych innych ustaw (Dz.U. z 2015 r. poz. 875).*](https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20150000875) 
72. [â†‘](#cite_ref-72) <https://web.archive.org/web/20160331074842/https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en>
73. [â†‘](#cite_ref-73) <https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter/2011-10-konsoliderad>
74. [â†‘](#cite_ref-74) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
75. [â†‘](#cite_ref-75) ["Corporate report - Controlled Drugs"](https://www.gov.uk/government/publications/controlled-drugs). Government Digital Service. Retrieved December 19, 2019. 
76. [â†‘](#cite_ref-76) Controlled Drugs and Substances Act | <http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm>